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Abstract 
Vascular Consequences of Metabolic Syndrome Related Shifts in 
Cyclooxygenase Mediated Arachidonic Acid Metabolism 
 
Adam G. Goodwill 
 
The metabolic syndrome is a multi-faceted disease state in which the initial 
pathology of obesity leads to the development of a cadre of comorbidities including, but 
not limited to, atherogenic dyslipidemia, a prothrombotic state, a proinflammatory state, 
a pro-oxidant state, hypertension and type II diabetes mellitus.  The prevalence of 
obesity is drastically increasing both nationally and globally, indicating that 
understanding obesity related disease is more relevant now then ever before.  The 
metabolic syndrome has been demonstrated to result in numerous deleterious 
consequences for afflicted individuals, not the least of which is peripheral vascular 
disease.  While the study of peripheral vascular disease has been extensively 
conducted and a robust body of literature exists implicating alterations in vasomotor 
regulation as the etiology for demand:perfusion mismatches in peripheral tissues, little 
study has been conducted to determine the consequences of metabolic syndrome on 
vascular network structure and the perfusion outcomes of the alterations to that 
network. 
Our lab has previously demonstrated that with metabolic syndrome comes a 
progressive loss of microvessel density in skeletal muscle, termed rarefaction.  This 
rarefactive phenomenon has been established in other animal models as well as in 
humans, however, the mechanistic underpinnings of microvascular rarefaction still 
require significant investigation.  For this reason we set out to: 
1. Identify the significant physiologic correlates/predictors of microvascular 
rarefaction. 
2. Determine which correlates played a contributing role in the development of 
rarefaction. 
3. Better establish a time-course for the phenomenon of rarefaction in our 
experimental model; the obese Zucker rat. 
The results of these studies demonstrate that alterations to inflammatory status and 
elevated oxidant stress significantly contribute to the development of obesity related 
rarefaction.  Additionally, these two causative-agents act through intermediaries either 
shifting the balance in endogenous prostanoid production to a preferential generation of 
TxA2, or diminishing vascular nitric oxide bioavailability.  Additionally, it was discovered 
that in the obese Zucker rat, rarefaction is a biphasic process wherein the phases are 
mechanistically distinct from one another.  The initial or early phase of rarefaction is 
mediated by elevations in TxA2 production, whereas later rarefaction is mediated by 
diminished vascular nitric oxide bioavailability.  Taken together, these data indicate that 
rarefaction is a process whose origins are rooted in the very earliest development of 
metabolic syndrome.  The process itself is more mechanistically complex than initially 
anticipated and is mediated by pathologic alterations (elevated oxidant stress and 
altered inflammatory profile) which have been shown to produce additional deleterious 
effects.  These studies would indicate that a greater knowledge of the origins and 
regulation of alterations to inflammatory status and elevations in oxidative stress are 
essential in treating metabolic syndrome. 
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Chapter 1 
 
 
The Metabolic Syndrome 
  
1
The metabolic syndrome is a term given to a constellation of comorbidities 
manifested within a single individual and owing to the initiating condition of obesity.  The 
term itself has been in common, though poorly defined, usage as early as the 1950s.  
The first appearance of the term “metabolic syndrome” in a peer reviewed journal 
indexed by PUBMED was by an Israeli group in 1972 (11).  Though they were the only 
group to publish a manuscript employing the term metabolic syndrome in that year, by 
1977, the term began to be used annually in a limited number of publications and it was 
in the early 1990s that the study of metabolic syndrome became mainstream with 
publication numbers rising from two in 1990 to 113 in 1999 with the trend continuing to a 
startling 3734 publications containing the term metabolic syndrome in 2010 (See Figure 
1).  
 This impressive growth in metabolic syndrome research directly parallels the 
growth in numbers of obese individuals here in the United States and abroad.  
According to the National Health and Nutrition Examination Surveys, approximately 
33.8% of Americans are obese (BMI >30) with a nearly equivalent percentage meeting 
the criteria for overweight (BMI >25) (4).  Sampling back to 1960 demonstrates a near 
exponential rise in the number of obese individuals starting in 1980 and continuing to 
the turn of the century (See Figure 2) (15).   Fortunately it appears that this 
phenomenonal growth in obesity is beginning to plateau, though extensive speculation 
exists attributing the plateau to ever diminishing numbers of individuals whose BMI falls 
below 25 remaining to enter into overweight or obese categories.  It is worth noting that 
while some regionality does exist with regards to the BMI of an average citizen, when 
examined by state it becomes apparent that there are no startlingly obese states 
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causing a shift in the statistics as the current distribution ranges from 21% in Colorado 
to 34% in Mississippi (1).  This trend in obesity shows no evidence of significant future 
abatement as approximately 17% of children age 2-19 are already obese (14).  It is in 
this overweight and obese population of children, adolescents and adults that you will 
find those individuals with the predisposing characteristics for development of metabolic 
syndrome and it is because of the high prevalence of obesity that approximately 34% of 
all adult Americans met the diagnostic criteria for metabolic syndrome in 2006 (3). 
A problem that metabolic syndrome research has suffered for a number of years 
is an unsatisfactory definition for the diagnostic criteria of the syndrome itself.  The 
combination in increase of incidence/prevalence of metabolic syndrome paired with the 
drastic increase in metabolic syndrome directed research efforts globally led the 
American Heart Association to set guidelines for the definition of metabolic syndrome in 
the National Cholesterol Education Program’s Adult Treatment Panel III report in 2004 
(9).   In this panel, six key components of metabolic syndrome were identified: 
abdominal obesity, atherogenic dyslipidemia, hypertension, a proinflammatory state, a 
prothrombotic state and insulin resistance with or without glucose intolerance.  It was 
further stated that abdominal obesity, clinically presented as increased waist 
circumference, was both the strongest predictor of metabolic syndrome as well as a key 
contributor to all other identified comorbidities (9).  To meet the diagnostic criteria of 
metabolic syndrome, a single individual must present with a minimum of three of the 
above listed pathologies (9). 
The metabolic syndrome can be thought of in lay-terms as an increase in the 
chance of a negative outcome subsequent to a cardiovascular event.  This is due to the 
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multifaceted complications that the metabolic syndrome presents to the vasculature 
itself (13).  Highlighted vascular deficits included within the syndrome are: increased 
vascular tone, increased incidence of atheroma formation, increased incidence of 
thrombus formation, endothelial dysfunction, vascular wall remodeling, and vascular 
network remodeling (6; 13).  The outcome of this integrated vascular system 
dysfunction with the greatest impact on quality of life is peripheral vascular disease, 
wherein perfusion cannot be appropriately regulated to match changes in metabolic 
demand (2; 5).  This results in an obese individual who becomes obese as a result of an 
imbalance in caloric homeostasis and ultimately remains obese due to an inability in 
peripheral skeletal tissues to adequately supply blood flow to reverse this imbalance (5; 
6).  In other words, people go from being obese because of a lack of appropriate 
exercise to meet their caloric intake to being unable to increase their caloric 
consumption by skeletal muscle due to inadequate perfusion. 
The work detailed within this document investigates the role of metabolic 
syndrome induced alterations in cyclooxygenase mediated arachidonic acid metabolism 
in skeletal muscle microvascular disease.  Initial investigations will demonstrate the role 
of these alterations in vasomotor dysfunction in animal models of metabolic syndrome 
but which ultimately serve as the foundational work for the investigation into the role of 
this shift in the progressive loss of microvessel density (rarefaction) demonstrated within 
the syndrome.  By the conclusion of this document, it is the author’s intention to 
demonstrate a significant role for the shift in arachidonic metabolism in causing 
microvascular rarefaction and identify prospective, potentially clinically relevant targets 
for intervention meriting future investigation. 
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Endothelial Dysfunction 
Endothelial dysfunction is generically a loss of normal physiologic function in the 
vascular endothelium with regards to barrier, anti-thrombotic character, regulatory, 
vasomotor, etc (18; 20; 23).  Of particular relevance to the metabolic syndrome are the 
vasomotor consequences of endothelial dysfunction which can be defined as a 
diminished responsiveness of the vascular endothelium to vasodilator stimuli (primarily 
mediated through NO and prostacyclin; collectively termed endothelial derived relaxing 
factors) along with exaggerated responses to constrictor stimuli (6).   This is a major 
cause of disparities in demand:perfusion matching in the peripheral tissues in metabolic 
syndrome subjects.  In addition to being a hallmark of the metabolic syndrome, 
endothelial dysfunction is one of the most extensively studied vasculopathies today.  
Particular attention is paid to the role of endothelial nitric oxide synthase (eNOS) in the 
endothelial dysfunction literature. 
As previously stated, endothelial dysfunction is defined, in part, by a diminished 
responsiveness of the vasculature to endothelium dependent vasodilator stimuli.  The 
mechanisms by which these impairments can occur are varied and not mutually 
exclusive.  They include scavenging of the endothelium derived relaxing factors 
(EDRF), diminished production of the EDRF, functional antagonism by a 
vasoconstrictive force, inability of the EDRF to reach the effector sites and decreased 
responsiveness of the vascular smooth muscle to the EDRF.  Numerous studies have 
demonstrated that individuals and experimental animals with metabolic syndrome suffer 
from endothelial dysfunction (5; 17).  Many of these studies have further demonstrated 
the role of ROS in the etiology of endothelial dysfunction in metabolic syndrome 
5
subjects with additional studies demonstrating the therapeutic potential of antioxidants 
in treatment of the dysfunction (21; 25) as well obesity associated acute myocardial 
infarctions (12).  Since a major portion of this manuscript deals with the alterations in 
arachidonic acid metabolite balance, prostacyclin will be discussed in subsequent 
sections whereas a brief overview of eNOS and NO is detailed below. 
The primary function of eNOS is the conversion of L-arginine to L-citrulline, 
resulting in the release of the potent vasodilator, nitric oxide (NO), as a reaction side 
product.  While this role is well established, more recent studies of vascular pathologies 
have also had cause to focus on a phenomenon termed eNOS uncoupling.  In eNOS 
uncoupling, limiting concentrations of either L-arginine or the cofactor 
tetrahydrobiopterin (BH4) cause eNOS to demonstrate a NADPH oxidase-like activity 
resulting in the production of O2- (16).  Depletion of BH4 does not necessarily stem from 
a metabolic inadequacy in all cases.  Studies have demonstrated that peroxynitrite can 
oxidize the essential cofactor for eNOS activity, tetrahydrobiopterin (BH4) thereby 
uncoupling eNOS (24).  In a sense this is a feedback loop as peroxynitrite is the product 
of the interaction between superoxide and NO.  Therefore, with a modest increase in 
global oxidant stress comes the potential for a positive feedback loop wherein a small 
production of peroxynitrite can in turn scavenge BH4, thereby uncoupling eNOS 
resulting in the production of superoxide which could in turn interact to produce 
additional peroxynitrite and so on.  This serves as a mechanism by which global oxidant 
stress can not only increase ROS production through secondary pathways but also 
attenuate the production of normal vaso-regulatory compounds. 
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 Additionally, since peroxynitrite is generated by the interaction of O2- with NO, as 
previously discussed, the effect on the systemic vasculature is exaggerated by both 
scavenging the existing NO and altering the catalytic activity of eNOS blocking further 
NO production.  Peroxynitrite is not, however, alone in its ability to crosstalk and 
uncouple eNOS.  Angiostatin, high glucose, ceramide, homocysteine and hypochlorous 
acid have all been shown to promote uncoupling in cultured endothelial cells.   
Microvascular Rarefaction 
 Generically, rarefaction is a term defining any process wherein your subject or 
target of interest becomes less prevalent.  In the case of microvascular rarefaction, this 
means that the arterioles and capillaries within a tissue of interest are becoming less 
prevalent when compared between conditions.  The metabolic syndrome, demonstrates 
the process of microvessel rarefaction in skeletal muscle tissues when comparing 
between comparable lean and obese animals or humans.  The consequence of this 
rarefactive process is the inability to match tissue demand and perfusion even in 
maximally dilated vascular beds.  This was clearly demonstrated in 2003 in work by 
Frisbee et al. showing that the consequence of significant rarefaction is a true structural 
inability to match demand and perfusion resulting in a disparity with no short term 
temporal solution. 
While the fact of rarefaction is established, the mechanisms of rarefaction have 
classically been poorly understood.  In metabolic syndrome, rarefaction has been 
attributed to hypertension, dyslipidemia, insulin sensitivity, and vascular NO 
bioavailability.  Using a technique first pioneered by Greene et al., (8) we are able to 
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examine skeletal muscle microvessel density in animal models of metabolic syndrome 
rapidly and with high resolution.  In this document, we will demonstrate that the process 
of rarefaction is a multi-mechanistic continuum of problems resulting in diminished 
tissue capillarity in the skeletal muscle of metabolic syndrome animal models. 
Arachidonic Acid Metabolism 
 Arachidonic acid (AA) is stored in the membranes of nearly all known mammalian 
cells bound to membrane phospholipids.  It can be released from this stored state by 
the actions of phospholipase A, phospholipase C or phospholipase D.  As 
phospholipase A is capable of releasing AA in a single step as opposed to the multistep 
processes of phospholipases C & D, it is generally the focus of the most research 
attentions.  Subsequent to phospholipase mediated release from the plasma 
membrane, free vascular AA has 3 basic fates.  It can be reincorporated into the plasma 
membrane bound once again to membrane phospholipids, it can diffuse away in the 
bloodstream to distal locations or it can diffuse into the cytoplasmic space of the cell.  If 
AA diffuses into the cytoplasm, it is enzymatically degraded down one of three major 
enzymatic pathways: the cyclooxygenase pathway (COX), the lipoxygenase pathway 
(LOX) or the cytochrome P450 pathway (CYP450). 
 The cyclooxygenase pathway is the major enzymatic producer of a class of 
compounds known as prostanoids.  These metabolic end-products of AA metabolism 
are the result of the activity of cyclooxygenase converting AA into prostaglandin H2.  
Prostaglandin H2 itself serves as the precursor to all series 2 prostanoids including 
prostacyclins, thromboxanes and prostaglandins.  While all 3 categories of series 2 
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prostanoids have been shown to produce numerous biological effects, prostacyclin and 
thromboxane generally receive the greatest attention in the cardiovascular literature as 
there is extensive evidence indicating both classes of compounds are key regulators of 
vasomotor tone in specific physiologic and pathophysiologic conditions. Classically 
these vascular considerations of thromboxane and prostacyclin are limited to the 
vasomotor as they are a potent vasoconstrictor and vasodilator, respectively. 
 Alternative to the cyclooxygenase pathway is the 5, 12, 15 lipoxygenase 
pathway.  This family of enzymes is responsible for catalyzing the conversion of 
arachidonic acid into a family of compounds collectively referred to as the leukotrienes.  
Leukotrienes are not considered to be major regulators of vascular tone as their effects 
are more relevant in the mediation of immune responses.  Leukotriene A4 in particular 
has been implicated strongly in allergic asthma though its effects are not unique to that 
condition.  Neutrophil recruitment, direct tracheal smooth muscle contraction, 
sustainment of inflammatory responses and acute allergic actions have all been 
attributed to leukotriene dependent processes. 
 The final pathway for the enzymatic metabolism of arachidonic acid is the CYP 
450 pathway.  This pathway can be broken into two subcategories: the epoxygenase 
pathway and the ω-hydroxylase pathway.  While both pathways are controlled by the 
activity of p-type-cytochromes and act on the same precursor, the epoxygenase 
pathway generates a class of compounds known as epoxyeicostreienoic acids (EETs) 
while the ω-hydroxylase pathway is responsible for the production of 
hydroxyeicosatetraenoic acid (HETES).  While roles for both classes of compounds 
have been indicated in the regulation of vascular tone, as well as roles in inflammation 
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and oxidative stress, the studies contained herein failed to establish a role for CYP450 
metabolites of AA and as such further discussion of these pathways will not be included. 
 Alterations in AA metabolism can have direct effects on vasomotor function. 
Increases in vascular oxidant stress can lead to shifts in the metabolism of AA through 
the COX pathway independent of the direct effects of ROS on prostacyclin synthase.  
Studies performed in the obese Zucker rat demonstrate that with changes to vascular 
oxidant stress, comes a shift in the metabolism of arachidonic acid through the COX 
pathway from a predominant production of prostacyclin to a predominant production of 
thromboxane (TXA2) in response to hypoxia (7).  The net effect of this shift is a blunted 
vasodilation in response to a highly specific vasodilator stimulus.  This finding has been 
supported by additional studies which have demonstrated increased production of the 
vasoconstrictors PGH2 (19), PGF2α (22) and TXA2 (10) along with diminished 
prostacyclin production in the diabetic experimental animals.  This shift in arachidonic 
acid metabolism to the generation of greater production of vasoconstrictor stimuli serves 
to blunt the response of the endothelium to vasodilator stimuli as the vasodilator 
functions are masked by the tonic vasoconstrictive forces.  While these effects have 
been documented within the literature, this manuscript will set out to establish a role for 
alterations in AA metabolism which stretch beyond the vasomotor and show 
demonstrable, significant, deleterious effects on vascular network structure. 
Conceptual Framework for Subsequent Chapters 
 Due to the fact that the majority of remaining chapters in this document were 
originally intended as stand-alone texts, the logic linking each chapter to its predecessor 
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and successor may not be immediately apparent.  As such, we present here a 
conceptual framework in which to consider each manuscript contained within this body 
of work as a part of a greater intellectual approach to the study of vascular 
consequences of metabolic syndrome and the roles of arachidonic acid metabolites in 
these pathophysiologic processes.  Chapter 2 of this document is entitled “Increased 
Vascular Thromboxane Generation Impairs Dilation of Skeletal Muscle Arterioles of 
Obese Zucker Rats with Reduced Oxygen Tension.”  This chapter is the foundational 
work upon which the author has continued his experimental designs through the course 
of his graduate education.  It makes the initial observation that when a highly specific 
stimulus for vascular prostacyclin production, hypoxia, is employed in both lean and 
obese Zucker rats, there is a blunted dilation with obesity that is mediated exclusively by 
a shift from a predominant production of prostacyclin to a blunted prostacyclin and 
exaggerated thromboxane generation response.  Additionally, this chapter provides 
some of the initial experiments indicating a role for elevations in oxidant stress as 
mediators for elevations in thromboxane generation. 
 Chapter 3 of this document is entitled “Increased Arachidonic Acid-Induced 
Thromboxane Generation Impairs Skeletal Muscle Arteriolar Dilation with Genetic 
Dyslipidemia.  In this chapter, we leave the obese Zucker rat model and instead focus 
on two genetic variants of the C57/Bl/6J mouse with specific gene deletions of either the 
low density lipoprotein receptor or the apolipoprotein E gene resulting in an animal 
model of familial hypercholesterolemia or type III hyperlipidemia respectively.  In this 
study we demonstrate that in an animal model of hypercholesterolemia, a comorobidity 
of metabolic syndrome, AA metabolism shifts in a directionally consistent manner with 
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the more complex disease state of metabolic syndrome.  Additionally, this manuscript 
provides further evidence for elevations in ROS as a mediator of the shift in AA 
metabolites. 
 Chapter 4 of this manuscript is titled “Impact of Chronic Anticholesterol Therapy 
on Development of Microvascular Rarefaction in the Metabolic Syndrome.”  This 
chapter returns to the obese Zucker rat model investigating how statin and fibrate 
therapies affect progression of skeletal muscle microvascular rarefaction in the 
metabolic syndrome.  This paper, interestingly, demonstrates that protective effects of 
statin therapies can be conferred with regards to rarefaction, however, these effects are 
independent of plasma cholesterol levels and seem to be mediated by the pleiotropic 
effects in diminishing oxidative stress and inflammatory status.  This paper serves a 
critical role in further demonstrating that microvascular rarefaction in fully developed 
metabolic syndrome animal models strongly correlates with diminished vascular NO 
bioavailability and that protection against microvessel loss is only conferred by those 
therapeutics capable of protecting against the loss of NO bioavailability. 
 The culmination of these ongoing investigations into metabolic syndrome related 
microvascular rarefaction is presented in Chapter 5 entitled, “Temporal Progression of 
Microvascular Rarefaction in the Metabolic Syndrome; The Role of Thromboxane A2.”  
This incomplete work shows the preliminary investigations into a higher resolution, 
temporal analysis of the process of rarefaction in metabolic syndrome.  It clearly 
demonstrates a biphasic rarefactive process mediated in the early phase by elevations 
in thromboxane A2 levels and in the later phase by diminished vascular NO 
bioavailability. This chapter provides the evidence that the early alterations to COX 
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mediated AA metabolism have effects that extend beyond the vasomotor with significant 
impact on vascular network structure through the life of the animal. 
 Supplementary materials which may provide a greater appreciation for the work 
presented within this manuscript include “Differential Impact of Familial 
Hypercholesterolemia and Combined Hyperlipidemia on Vascular Wall and Network 
Remodeling in Mice” by Stapleton et al. which provides some of the foundational 
correlative data between elevation in TxA2 production and changes to vascular wall 
mechanics in hyperlipidemic mice.  Additional insight into the significance of this work 
can be found in the article entitled “Aspirin Resistance with Genetic Dyslipidemia: 
Contribution of Vascular Thromboxane Generation” by Frisbee et al. which was also 
performed in dyslipidemic mice and highlights why inhibition of COX is a poor 
therapeutic target in an animal model with a single metabolic syndrome comorbidity and 
helps to better explain why our investigations into metabolic syndrome related skeletal 
muscle microvascular rarefaction employ more selective inhibition of enzymes 
downstream from COX as opposed to general COX inhibition which may be more 
clinically employed though, plausibly, less therapeutically relevant. 
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FIGURE LEGENDS 
Figure 1.   This figure legend is directly taken, as is the figure from the associated 
citation: Age adjusted by the direct method to the year 2000 U.S. Census Bureau 
estimates, using the age groups 20-39, 40-59, and 60-74 years.  Pregnant females 
were excluded.  Overweight is defined as a body mass index (BMI) of 25 or greater but 
less than 30; obesity is a BMI greater than or equal to 30; extreme obesity is a BMI 
greater than or equal to 40. Source: CDC/NCHS, National Health Examination Survey 
cycle 1 (1960-1962); National Health and Nutrition Examination Survey (1971-1974), II 
(1976-1980), and III (1988-1994), 1999-2000, 2001-2002, 2003-2004, 2005-2006, and 
2007-2008. (15) 
 
Figure 2.   Annual usage of the term “metabolic syndrome” as determined by an 
independent search of PUBMED. 
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 ABSTRACT 
This study determined if altered vascular prostacyclin (PGI2) and/or thromboxane (TxA2) 
production with reduced PO2 contributes to impaired hypoxic dilation of skeletal muscle 
resistance arterioles of obese Zucker rats (OZR) vs. lean Zucker rats (LZR).  
Mechanical responses were assessed in isolated gracilis muscle arterioles following 
reductions in PO2 under control conditions and following pharmacological interventions 
inhibiting arachidonic acid metabolism, nitric oxide synthase, and alleviating elevated 
vascular oxidant stress.  Production of arachidonic acid metabolites was assessed using 
pooled arteries from OZR and LZR in response to reduced PO2.  Hypoxic dilation, 
endothelium-dependent in both strains, was attenuated in OZR vs. LZR.  NOS inhibition 
had no significant impact on hypoxic dilation in either strain.  COX inhibition dramatically 
reduced hypoxic dilation in LZR and abolished responses in OZR.  Treating arterioles 
from OZR with PEG-SOD improved hypoxic dilation, and this improvement was entirely 
COX-dependent.  Vascular PGI2 production with reduced oxygen tension was similar 
between strains, although TxA2 production was increased in OZR; a difference that was 
attenuated by treatment of vessels from OZR with PEG-SOD.  Both blockade of 
PGH2/TxA2 receptors and inhibition of thromboxane synthase increased hypoxic dilation 
in OZR arterioles.  These results suggest that a contributing mechanism underlying 
impaired hypoxic dilation of skeletal muscle arterioles of OZR may be an increased 
vascular production of TxA2, which competes against the vasodilator influences of PGI2.  
These results also suggest that the elevated vascular oxidant stress inherent in the 
metabolic syndrome may contribute to the increased vascular TxA2 production and may 
blunt vascular sensitivity to PGI2.   
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 INTRODUCTION 
 The metabolic syndrome represents a series of systemic pathologies that develop 
sequentially in afflicted individuals, and can include obesity, insulin resistance/type II 
diabetes mellitus, dyslipidemia and hypertension (25).  While each of these pathologies in 
isolation can increase the future risk for development of peripheral vascular disease, when 
present in combination this risk increases dramatically (24), and can lead to numerous 
profound alterations to vascular structure/function relationships (26, 27).  These vascular 
alterations can impair to tissue perfusion:demand matching and can lead to a 
compromised function (27).  An effective animal model for the metabolic syndrome in 
humans is the obese Zucker rat (OZR), a rodent model characterized by its dysfunctional 
leptin receptor gene, resulting in abrogated leptin signaling and an impaired satiety reflex 
(10).  As a result, the OZR experiences a chronic hyperphagia, and sequentially develops 
each of the systemic pathologies listed above, in addition to both pro-oxidant and pro-
inflammatory states (1, 6, 22).  Previous studies by multiple investigative groups have 
demonstrated negative vascular outcomes in OZR with development of the metabolic 
syndrome, including alterations to vascular wall mechanics (4, 13, 28, 29), impairments to 
multiple indices of dilator reactivity (9, 13, 15, 16, 33), signaling mechanisms underlying 
constrictor reactivity (17, 21, 30) and a rarefaction of microvascular networks within multiple 
tissues (7, 8, 31).  The culmination of these alterations to microvascular structure and 
function within OZR can result in profound impairments to the perfusion of tissue under an 
array of physiological and pathological conditions (8, 12, 33).   
 We have previously demonstrated that the dilator reactivity of skeletal muscle 
resistance arterioles in response to an acute reduction in oxygen tension is impaired in 
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 OZR compared to LZR, and that a contributing mechanism to this impairment lies within 
the chronic elevation in vascular oxidant stress (9).   However, while this previous study did 
not implicate specific mechanisms beyond the contribution of elevated vascular oxidant 
stress, recent studies from Hester’s group have provided data which may have 
considerable bearing on not only our previous observation, but also on the integrated 
regulation of vascular reactivity in the skeletal muscle of OZR (32, 33).  Specifically, the 
dilator response of in situ spinotrapezius muscle arterioles with increased metabolic 
demand, previously determined to be a largely dependent on vascular production of 
prostacyclin (PGI2, Ref. 11), was blunted in OZR compared to LZR.  This observation may 
reflect an enhanced vascular production of thromboxane A2 (TxA2), or elevated 
vasoconstrictor response to TxA2 within OZR that is not present in lean animals (32, 33).  
Clearly, any increase in TxA2 production has the potential to compete against PGI2-
mediated responses and impair dilator reactivity to multiple vasoactive stimuli. 
 The purpose of the present study was to more fully elucidate mechanisms 
contributing to the impaired dilation of skeletal muscle arterioles of OZR in response to 
reduced PO2.  Additionally, the present study was designed to more clearly determine the 
role for elevated vascular oxidant stress in contributing to the attenuated hypoxic dilation of 
arterioles from OZR.  Specifically, the hypothesis tested by the present experiments was 
that the compromised dilator reactivity of skeletal muscle arterioles of OZR in response to 
reduced PO2 compared to responses in LZR is due to a reduction in the vascular 
production of PGI2 and an increased vascular production of TxA2 as a result of the acute 
reductions in oxygen tension.  Further, these effects on PGI2 and TxA2 production will be 
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 the result of an elevation in vascular oxidant stress, altering arachidonic acid metabolism 
within arterioles of OZR.  
MATERIALS AND METHODS 
Animals: 15-17 week old male lean and obese Zucker rats (LZR and OZR, respectively) 
were used for all experiments.  Rats were fed standard chow and tap water ad libitum, and 
all protocols received prior IACUC approval.  After an overnight fast, rats were 
anesthetized with injections of sodium pentobarbital (50 mg•kg-1 i.p.), and received tracheal 
intubation to facilitate maintenance of a patent airway.  In all rats, a carotid artery and an 
external jugular vein were cannulated for determination of arterial pressure and for 
intravenous infusion of supplemental anesthetic, if necessary.  While under anesthetic, an 
aliquot of blood was drawn from the jugular vein to be used for the biochemical 
determination of plasma glucose (Freestyle; Abbott Diabetes Care, Alameda, CA), insulin 
(Linco; St. Charles, MO), and nitrotyrosine concentrations (Linco; St. Charles, MO) as well 
as a plasma lipid profile (Stanbio; Boerne, TX) from each animal.   
Preparation of Isolated Skeletal Muscle Resistance Arterioles: In anesthetized rats, 
the intramuscular continuation of the gracilis artery was identified and surgically 
removed.  Arterioles were placed in a heated chamber (37°C) that allowed the vessel 
lumen and exterior to be perfused and superfused, respectively, with physiological salt 
solution (PSS; equilibrated with 21% O2, 5% CO2; 74% N2) from separate reservoirs.  
Vessels were cannulated at both ends and were secured to inflow and outflow glass 
micropipettes connected to a reservoir perfusion system allowing intralumenal pressure 
and gas concentrations to be controlled.  Arterioles were extended to their in situ length 
and were equilibrated at 80% of the animal's mean arterial pressure (Table 1).  Vessel 
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 diameter was measured using television microscopy and an on-screen video 
micrometer, and all mechanical responses of arterioles were assessed under 
pressurized conditions with no flow through the arteriolar lumen. 
 Subsequent to the initial equilibration period, the reactivity of isolated arterioles 
was assessed following challenge with reduced PO2 (ΔPO2 from ~135 mmHg [21% O2] 
– ~45 mmHg [0% O2]) under an array of physiological and pharmacological conditions 
(described below).  In an additional series of experiments, isolated arterioles were also 
challenged with increasing concentrations of the selective thromboxane A2 mimetic U-
46619 (10-12 M – 10-8 M; Biomol) and prostacyclin (PGI2•Na; 10-12 M – 10-8 M; Biomol) to 
determine the intrinsic sensitivity of microvessels to these stimuli.   
 Removal of the arteriolar endothelium was accomplished by passing an air bolus 
through the perfusate line into the isolated microvessel, the efficacy of which was 
determined from a loss of all dilator reactivity in response to application of 10-6 M 
acetylcholine.  To assess the contribution of nitric oxide production or the generation of 
metabolites via cyclooxygenase as mediators of arteriolar reactivity, isolated vessels 
were treated with the nitric oxide synthase inhibitor L-NG-nitroarginine methyl ester (L-
NAME; 10-4 M; Sigma) or the cyclooxygenase inhibitor indomethacin (INDO; 10-5 M; 
Sigma), respectively.  To antagonize vascular PGH2/TxA2 receptors, vessels were 
treated with SQ-29548 (10-5 M; Biomol), while inhibition of thromboxane synthase was 
accomplished using carboxyheptyl imidazole (CHI; 10-5 M; Biomol).  To reduce vascular 
oxidant stress, arterioles were treated with polyethylene glycol-superoxide dismutase 
(PEG-SOD; 200 U/ml; Sigma). 
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 Determination of Vascular Metabolites of Arachidonic Acid:  Vascular production of 6-
keto-prostaglandin F1α (6-keto-PGF1α; the stable breakdown product of PGI2; Refs. 18, 23), 
and 11-dehydro-thromboxane B2 (11-dehydro-TxB2; the stable plasma breakdown product 
of TxA2; Ref. 5) in response to challenge with reduced oxygen tension was assessed using 
pooled conduit arteries (femoral, saphenous, iliac) from LZR and OZR.  Pooled vessels 
from each animal were incubated in microcentrifuge tubes in 1 ml of physiological salt 
solution for 30 minutes under control conditions (21% O2).  After this time, the superfusate 
was removed, stored in a new microcentrifuge tube and frozen in liquid N2, while a new 
aliquot of PSS was added to the vessels and the equilibration gas was switched to 0% O2 
for the subsequent 30 minutes.  After the second 30 minute period, this new PSS was 
transferred to a fresh tube, frozen in liquid N2 and stored at -80°C.  Metabolite release by 
the vessels was determined using commercially available EIA kits for 6-keto-PGF1α and 11-
dehydro-TxB2 (Cayman). 
Data and Statistical Analyses:  Active tone of individual arterioles at the equilibration 
pressure was calculated as (ΔD/Dmax)•100, where ΔD is the diameter increase from rest 
in response to Ca2+-free PSS, and Dmax is the maximum diameter measured at the 
equilibration pressure in Ca2+-free PSS.   
 Mechanical responses of isolated arterioles following challenge with increasing 
concentrations of thromboxane or prostacyclin were fit with the three-parameter logistic 
equation: 
⎥⎦
⎤⎢⎣
⎡
+
−+= −xECy 50log101
minmaxmin  
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 where y  represents the change in arteriolar diameter, “min” and “max” represent the 
minimum and maximum bounds, respectively, of the change in arteriolar diameter with 
increasing agonist concentration, x  is the logarithm of the agonist concentration and 
50logEC  represents the logarithm of the agonist concentration ( x ) at which the response 
( y ) is halfway between the minimum and maximum bounds.     
 Data are presented as mean±SEM.  Statistically significant differences in the 
magnitude of hypoxic dilation, vascular production of 6-keto-PGF1α and 11-dehydro-TxB2, 
and the calculated parameters describing the thromboxane or prostacyclin concentration-
response relationships were determined using analysis of variance (ANOVA).  In all cases, 
Student-Newman-Keuls post hoc test was used when appropriate and p<0.05 was taken to 
reflect statistical significance.   
RESULTS 
 Table 1 presents baseline characteristics of LZR and OZR in the present study.   At 
15-17 weeks of age, OZR demonstrated profound obesity, severe insulin resistance, and 
dyslipidemia characterized by moderate hypercholesterolemia and severe 
hypertriglyceridemia.  In addition, OZR also presented a moderate elevation in mean 
arterial pressure as compared to LZR.  Plasma levels of nitrotyrosine, a protein marker of 
chronic elevations in oxidant stress, were significantly elevated in OZR compared to LZR.  
With regard to basal vascular tone, isolated arterioles from both rat strains demonstrated a 
comparable resting active diameter, although passive diameter was reduced in OZR 
versus LZR.  However, this remodeling of the vessel wall did not translate into a difference 
in calculated active tone between the strains. 
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  Data summarizing hypoxic dilation of resistance arterioles from LZR and OZR are 
presented in Figure 1.  As shown in Panel A, arterioles from OZR exhibited a blunted 
dilator response to reduced PO2 compared to vessels from LZR.  However, arteriolar 
reactivity to reduced oxygen tension was abolished in both groups following removal of the 
vascular endothelium.  Panel B presents data describing the contribution of nitric oxide 
synthase (NOS) and cyclooxygenase (COX) products to arteriolar dilation in response to 
reduced PO2 in LZR and OZR.  While NOS inhibition has a consistently minor, albeit 
statistically insignificant, blunting of hypoxic dilation in arterioles of LZR, treatment of 
vessels with L-NAME had no discernible impact on this response in OZR.  In contrast, 
incubation of vessels with indomethacin dramatically reduced hypoxic dilation in arterioles 
from both strains.  Combined treatment with L-NAME and indomethacin abolished all 
vascular responses to reduced PO2 in both LZR and OZR.  Panel C presents the impact of 
pre-treatment of arterioles with the anti-oxidant PEG-SOD on both the magnitude of 
hypoxic dilation in these vessels and on the contributions from NOS and COX.  Treatment 
of vessels with PEG-SOD had no significant impact on either the magnitude of hypoxic 
dilation or on the contribution of NOS and COX products to this response in LZR.  In 
contrast, following incubation with PEG-SOD, arterioles from OZR exhibited an improved 
dilation in response to reduced PO2, and this enhanced reactivity was entirely dependent 
on COX metabolism. 
 Figure 2 presents data describing the production of 6-keto-PGF1α (the stable 
breakdown product of PGI2) and 11-dehydro-TxB2 (the stable breakdown product of TxA2) 
from pooled vessels of LZR and OZR in response to reduced PO2.  As shown in Panel A, 
vessels from both LZR and OZR demonstrated a significant increase in 6-keto-PGF1α 
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 production in response to reduced PO2, although this increase was greater in LZR as 
compared to OZR.  In both cases, treatment of vessels with indomethacin abolished 6-
keto-PGF1α production in response to reduced oxygen tension.  With regard to the vascular 
production of TxA2, vessels from both LZR and OZR exhibited a significant increase in 11-
dehydro-TxB2 production following exposure to reduced PO2, although this level of 
production was dramatically elevated in vessels from OZR (Panel B).  In both cases, 
production of 11-dehydro-TxB2 was abolished following treatment of vessels with either 
indomethacin or CHI, suggesting that all production of TxA2 was mediated via the actions 
of thromboxane synthase distal to COX. 
 Data describing the production of 6-keto-PGF1α and 11-dehydro-TxB2 in response to 
reduced PO2 in vessels from OZR subsequent to pre-treatment with PEG-SOD are 
summarized in Figure 3.  Treatment of vessels with PEG-SOD did not alter 6-keto-
PGF1α production in vessels from OZR compared to levels in untreated vessels (Panel A).  
However, as compared to levels determined in untreated vessels, incubation of arteries 
from OZR with PEG-SOD blunted the enhanced production of 11-dehydro-TxB2 (Panel B)  
Treatment of vessels with indomethacin abolished reduced PO2-induced production of 6-
keto-PGF1α and 11-dehydro-TxB2. 
 Figure 4 presents data summarizing the dilator responses of arterioles from LZR 
and OZR in response to reduced PO2 following antagonism of either the PGH2/TxA2 
receptor with SQ-29548 or thromboxane synthase with CHI.  While neither of these 
pharmacological interventions had a consistent and significant impact on response in 
vessels from LZR, both SQ-29548 and CHI significantly increased hypoxic dilation in 
arterioles from OZR. 
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  Arteriolar reactivity in response to challenge with increasing concentrations of 
thromboxane or prostacyclin is summarized in Figure 5.  Arteriolar constriction in response 
to increasing concentrations of thromboxane was not different between LZR and OZR, and 
neither EC50 nor maximum bound were impacted in response to pre-treatment of the 
vessels with PEG-SOD (Panel A).  Further, arteriolar responses to thromboxane were 
abolished in vessels from both animal strains following incubation of the vessels with SQ-
29548 (Panel B).  With increasing concentrations of prostacyclin, arterioles from OZR 
exhibited a blunted dilator response compared to that determined in arterioles from LZR, 
and treatment of vessels with PEG-SOD significantly improved dilator reactivity to 
prostacyclin, although not to the level determined in LZR (Panel C).  EC50 was not 
significantly different between groups with regard to vascular reactivity in response to 
increasing concentrations of PGI2 (data not shown) 
DISCUSSION 
 Inherent within the development of the multi-pathology state that defines the 
metabolic syndrome is an array of alterations to vascular and microvascular structure and 
function that have the potential to profoundly impact the perfusion of tissues and organs, as 
well as the contributing mechanisms which comprise this integrated process.  Previous 
studies have clearly demonstrated that alterations to the patterns of vasodilator (8, 12) and 
vasoconstrictor (30) reactivity, as well as vessel wall remodeling (28, 29) and a reduction in 
microvessel density (7) all represent avenues through which vascular function and tissue 
perfusion can be compromised.  The purpose of the present study was to build on our 
previous observation of an impaired dilation of skeletal muscle resistance arterioles of OZR 
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 in response to acute reductions in oxygen tension, and the possible contributing role of 
elevated vascular oxidant stress in this process (9). 
 Comparable to our observations in the first study, hypoxic dilation of skeletal muscle 
resistance arterioles from OZR was significantly reduced compared to that determined in 
LZR (Figure 1, Panel A).  While this response was abolished following removal of the 
endothelium in both rat strains, comparable to the complete endothelium-dependence of 
hypoxic dilation in other rodent models (14, 19, 20), our results also support previous 
observations of a strong dependence on COX products in mediating hypoxic dilation of 
these vessels (18-20).   Interestingly, in our initial study we determined a small, but 
significant role for NOS activity in mediating hypoxic dilation in arterioles from LZR.  In the 
present study this effect was not statistically significant, suggesting that it may represent a 
minor contributor to arteriolar dilation in response to reduced oxygen tension in LZR.  
However, while the magnitude of this response is relatively minor in LZR, both the results 
from the present study and our previous one (9) indicate that this is completely lost with the 
development of the metabolic syndrome in OZR.  Additionally, pre-treatment of arterioles 
from OZR with the oxidative free radical scavenger PEG-SOD to lower the elevated 
oxidant stress in these animals resulted in a significant improvement to hypoxic dilation in 
the obese rats (Figure 1, Panel C).  This improvement to hypoxic dilation was confined to 
activity involving COX only, as treatment with indomethacin abolished hypoxic dilation in 
OZR, and treatment with L-NAME was without effect. 
 Recent studies from Hester’s group suggest that functional dilation (i.e., arteriolar 
dilation in response to elevated metabolic demand) is impaired in OZR as a result of 
alterations to arachidonic acid metabolism which can result in activation of thromboxane 
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 receptors causing a competing constrictor influence which acts to partially constrain dilator 
responses (32, 33).  Given that both functional dilation for in situ spintotrapezius muscle of 
LZR (11) and hypoxic dilation of skeletal muscle arterioles of LZR (9) has previously been 
shown to be strongly dependent on the vascular production of PGI2, we sought to 
determine if an alteration in arachidonic acid metabolism, resulting in an increased vascular 
production of thromboxane or a decreased production of prostacyclin may contribute to this 
impaired reactivity in arterioles of OZR.    As shown in Figure 2, arteries from OZR 
exhibited a significant increase in the production of PGI2 (estimated from measurements of 
6-keto-PGF1α) in response to reductions in oxygen tension.  While this was not as robust a 
response as that determined for arteries of LZR, it is unclear if this degree of attenuation in 
PGI2 production in OZR is sufficient to manifest itself as a blunted mechanical response.  In 
contrast, vascular production of TxA2 (estimated from measurements of 11-dehydro-TxB2), 
mildly elevated in arteries of LZR during reduced oxygen tension, was dramatically 
increased in vessels from OZR following exposure to reduced PO2.  Finally, while 
treatment of arteries from both strains with indomethacin abolished production of PGI2 and 
TxA2 in response to reduced oxygen tension, the treatment of vessels of OZR with CHI, an 
inhibitor of thromboxane synthase, severely reduced thromboxane production in vessels 
from OZR (Figure 2, Panel B).  These results suggest that reduced PO2 causes an 
increased production of TxA2 from vessels of OZR, mediated via thromboxane synthase, 
and that this may compete with the dilator influences of vascular production of PGI2.  
However, it should be emphasized that these results must be interpreted cautiously, as the 
production of metabolites of arachidonic acid was assessed using conduit arteries and not 
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 resistance arterioles, while the reverse is true with regard to the study of the mechanical 
responses. 
 In order to better understand the impact of elevated vascular oxidant stress on the 
impaired dilator responses to reduced PO2 in vessels of OZR, we treated vessels with 
PEG-SOD prior to exposure to reduced PO2 and determined the levels of 6-keto-PGF1α 
and 11-dehydro-TxB2 in the incubation superfusate (Figure 3).  These data suggest that 
while oxidant stress does not play a significant role in any reduction in the vascular 
production of prostacyclin (as the addition of PEG-SOD was without effect), elevated 
vascular oxidant stress may contribute to the increased production of thromboxane by 
these vessels, as incubation with the anti-oxidant significantly reduced the levels of 11-
dehydro-TxB2 in the superfusate.  However, this effect was not complete, as the levels of 
11-dehydro-TxB2 production remained elevated in the superfusate despite the presence of 
PEG-SOD, indicating that additional factors may contribute to thromboxane production in 
vessels of OZR which are independent of the effects of acute reduction in vascular oxidant 
stress.  This observation of a role for oxidant stress in shifting arachidonic acid metabolism 
toward an increased production of thromboxane has been identified previously (2, 3, 34), 
and the results of the present study suggest that a comparable effect may be occurring in 
the vasculature of OZR, with the net result of a blunted vascular response to stimuli that 
are dependent on PGI2 production for their full manifestation. 
 To better evaluate this statement, isolated skeletal muscle resistance arterioles from 
LZR and OZR were exposed to acute reductions in oxygen tension under control 
conditions and in response to either PGH2/TxA2 receptor blockade with SQ-29548 or 
thromboxane synthase inhibition with CHI (Figure 4).  Although these pharmacological 
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 challenges had no consistent impact on hypoxic dilation in arterioles from LZR, both 
interventions resulted in improved dilator reactivity in response to reduced PO2 in arterioles 
of OZR.  Taken with the previous results, these data clearly suggest that an increased 
production of TxA2 contributes to the impaired hypoxic dilation in arterioles of OZR.  
However, the data presented in Figure 4 do not allow for discrimination between increased 
vascular production of TxA2, an increased vascular sensitivity to produced TxA2, or an 
altered vascular sensitivity to produced PGI2.   
 In order to assess this final issue, isolated arterioles from both rat strains were 
challenged with increasing concentrations of thromboxane or prostacyclin (Figure 5).  
Vasoconstrictor reactivity to thromboxane was very similar between arterioles of LZR and 
OZR, and in both cases constrictor responses to thromboxane were largely independent of 
oxidant stress (i.e., no identifiable impact of treatment with PEG-SOD) and were abolished 
by blockade of the PGH2/TxA2 receptor.  These observations suggest that the vascular 
sensitivity to thromboxane is not significantly impacted by the presence of the metabolic 
syndrome.  In contrast, vascular reactivity to prostacyclin was significantly reduced in 
arterioles of OZR and this impairment was blunted following a reduction in oxidant stress 
with PEG-SOD.  Whether this impaired response to PGI2 represents oxidant radical 
degradation of prostacyclin (leading to the production of isoprostanes), altered function at 
the level of the prostacyclin receptor, the impact of elevated oxidant stress on the 
intracellular signaling cascade distal to the receptor, or a combination of these effects 
remains to be determined. 
 In summary, with the evolution of the metabolic syndrome in obese Zucker rats, the 
dilator responses of skeletal muscle resistance arterioles following acute reductions in 
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 oxygen tension are significantly attenuated.  Both biochemical and pharmacological 
evidence suggests that this impaired dilator reactivity may be the result of an increase in 
vascular production of thromboxane with reduced PO2 which could represent a constrictor 
influence which competes against the dilator effects of prostacyclin (the production of 
which appears to be largely intact).  Normalizing vascular oxidant stress blunts the 
increased reduced PO2-induced production of thromboxane in vessels from OZR and also 
increases the responsiveness of arterioles of OZR to exogenously supplied prostacyclin, 
thus leading to an improvement in the mechanical response of the vessel to reduced 
oxygen tension.  The present study provides no compelling evidence that skeletal muscle 
arteriolar sensitivity to thromboxane is altered with the progression of the metabolic 
syndrome.   
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 Table 1.  Baseline characteristics of LZR and OZR and for isolated arterioles in the present study.  * 
p<0.05 vs. LZR.      
 
  LZR OZR  
Mass (g) 361±7 664±9* 
MAP (mmHg) 108±4 124±4* 
[Glucose]blood (mg/dl) 102±5 184±11* 
[Insulin]plasma (ng/ml) 1.3±0.3 7.5±0.5* 
[Total Cholesterol]plasma (mg/dl) 89±9 137±11* 
[Triglycerides]plasma (mg/dl) 154±10 367±22* 
Nitrotyrosineplasma (ng/ml) 15±4 58±7* 
   
Inner Diameter – Active (μm) 104±4 102±5 
Inner Diameter – Passive (μm) 172±5 156±4* 
Active Tone (%) 39±2 35±3 
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 FIGURE LEGENDS 
Figure 1.  Dilator reactivity of isolated skeletal muscle resistance arterioles of LZR and 
OZR in response to acute reductions in oxygen tension.  Data, presented as mean±SEM, 
are shown for arterioles under control conditions and following removal of the vascular 
endothelium using air bolus perfusion (Panel A), inhibition of nitric oxide synthase with L-
NAME and/or inhibition of cyclooxygenase with indomethacin (Panel B), treatment with L-
NAME and/or indomethacin following incubation of the arteriole with the anti-oxidant PEG-
SOD (Panel C).  Please see manuscript text for complete details.  * p<0.05 vs. Control 
responses in that strain; † p<0.05 vs. responses in LZR Control; ‡ p<0.05 vs. responses in 
OZR + PEG-SOD. 
 
Figure 2.  Vascular production of 6-keto-PGF1α (Panel A; as an estimate of PGI2) and 11-
dehydro-TxB2 (Panel B; as an estimate of TxA2) by pooled arteries of LZR and OZR in 
response to an acute reduction in oxygen tension.  Data, presented as mean±SEM, are 
shown for arteries under control conditions, and following pharmacological inhibition of 
cyclooxygenases with indomethacin, and for 11-dehydro-TxB2, thromboxane synthase with 
CHI. * p<0.05 vs. Control (21% O2) in that strain, † p<0.05 vs. 0% O2 in that strain; ‡ 
p<0.05 vs. responses in LZR 0% O2. 
 
Figure 3.  Vascular production of 6-keto-PGF1α (Panel A; as an estimate of PGI2) and 11-
dehydro-TxB2 (Panel B; as an estimate of TxA2) by pooled arteries OZR in response to an 
acute reduction in oxygen tension.  Data, presented as mean±SEM, are shown for arteries 
under control conditions, following treatment of arteries with the anti-oxidant PEG-SOD, 
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 and following pharmacological inhibition of cyclooxygenases with indomethacin. * p<0.05 
vs. responses under Control (21% O2) conditions, † p<0.05 vs. responses under 0% O2; ‡ 
p<0.05 vs. responses determined under 0% O2 conditions + PEG-SOD. 
 
Figure 4.  Dilator reactivity of isolated skeletal muscle resistance arterioles of LZR and 
OZR in response to acute reductions in oxygen tension.  Data (mean±SEM) are presented 
for each strain under control conditions, and following pharmacological inhibition of the 
PGH2/TxA2 receptor with SQ-29548 or thromboxane synthase with CHI.   * p<0.05 vs. LZR 
Control; † p<0.05 vs. OZR Control.  
 
Figure 5.  Vascular reactivity of isolated skeletal muscle resistance arterioles of LZR and 
OZR (mean±SEM) in response to increasing concentrations of thromboxane under control 
conditions and following treatment of vessels with PEG-SOD (Panel A) or SQ-29548 
(Panel B), and increasing concentrations of prostacyclin under control conditions and 
following treatment with PEG-SOD (Panel C). The term “max” represents the maximum 
bound (the maximum change) in vessel diameter in response to increasing concentration 
of either thromboxane or prostacyclin; estimated from the logistic regression equation 
described in the “Materials and Methods”.  * p<0.05 vs. Control responses within that 
strain; † p<0.05 vs. responses in LZR under Control conditions. 
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 Figure 4. 
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 Figure 5. 
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ABSTRACT 
Objective: To determine if arachidonic acid (AA)-induced skeletal muscle arteriolar 
dilation is altered with hypercholesterolemia in ApoE and LDLR gene deletion mice fed 
normal diet.  This study also determined contributors to altered AA-induced dilation 
between dyslipidemic mice and controls; C57/Bl/6J (C57). 
Methods: Gracilis muscle arterioles were isolated, with mechanical responses assessed 
following challenge with AA under control conditions and after elements of AA 
metabolism pathways were inhibited.  Conduit arteries from each strain were used to 
assess AA-induced production of PGI2 and TxA2. 
Results: Arterioles from ApoE and LDLR exhibited a blunted dilation to AA versus C57.  
While responses were cyclooxygenase-dependent in all strains, inhibition of 
thromboxane synthase or blockade of PGH2/TxA2 receptors improved dilation in ApoE 
and LDLR only.  AA-induced generation of PGI2 was comparable across strains, 
although TxA2 generation was increased in ApoE and LDLR.  Arteriolar reactivity to 
PGI2 and TxA2 was comparable across strains.  Treatment with TEMPOL improved 
dilation and reduced TxA2 production with AA in ApoE and LDLR.  
Conclusions: These results suggest that AA-induced arteriolar dilation is constrained in 
ApoE and LDLR via an increased production of TxA2.  While partially due to elevated 
oxidant stress, additional mechanisms contribute which are independent of acute 
alterations in oxidant tone. 
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INTRODUCTION 
 Dyslipidemia, and specifically hypercholesterolemia, has repeatedly been 
demonstrated to represent a strong predisposing risk factor for the development of 
coronary and peripheral arterial disease (1).  While this increased risk for the progression 
of vascular disease with hypercholesterolemia is most commonly associated with an 
increased predisposition for the development of atherothromboses, atherosclerotic lesions 
and plaque depositions (3, 10, 26), investigations into the impact of hypercholesterolemia 
on vascular reactivity and endothelial function, potentially as contributing mechanisms to 
vascular disease, is less clearly understood.   
 While some disparity in the prevailing literature exists (25), the general consensus is 
that the development of hypercholesterolemia is usually associated with a significant 
reduction in the bioavailability of endothelium-derived nitric oxide (5, 6, 23), with the 
relatively predictable ensuing outcome of an impaired vascular reactivity in response to 
stimuli that are considered to have a significant contribution from this signaling 
molecule/pathway (i.e., flow-mediated dilation; ref. 12).  In our recent study, we provided 
evidence suggesting that development of familial hypercholesterolemia (a genetic disorder 
resulting in exceptionally high low density lipoprotein [LDL] level, in the face of an otherwise 
relatively normal lipid profile) in the LDL receptor gene deletion mouse or type III 
hyperlipidemia (a condition wherein both LDL and plasma triglycerides are significantly 
elevated) in the apolipoprotein E gene deletion mouse, was associated with a near 
complete abolition of the bioavailability of endothelium-derived nitric oxide in response to 
imposed stimuli (22).  However, this loss of vascular nitric oxide bioavailability did not result 
in a profound reduction in dilator reactivity, as an increased generation of dilator signaling 
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molecules through 12/15 lipoxygenases emerged with evolution of the dyslipidemia (22), 
suggesting that alterations to the metabolism of arachidonic acid may be associated with 
hypercholesterolemia, and that these can have profound consequences for vascular 
function.     
 In 1996, the work of Pfister and colleagues (16, 17) strongly suggested that diet-
induced hypercholesterolemia in rabbits can lead to changes in arachidonic acid 
metabolism, mediated via lipoxyegnase are cytochrome P450 epoxygenase enzymes, 
causing profound alterations to dilator reactivity determined in isolated aortic segments.  
Additionally, Srisawat et al. (21), while providing additional evidence that diet-induced 
hypercholesterolemia results in impaired endothelium-dependent dilation in aortic rings, 
determined that chronic treatment with indomethacin improved endothelial function, and 
was associated with reductions in urinary levels of 2,3-dinor-thromboxane B2 and 8-iso-
PGF2α, a stable urinary breakdown product of thromboxane A2 and a marker of chronic 
oxidant stress, respectively.  Most recently, Pfister demonstrated that impairments to 
endothelium-dependent dilation in aortic rings of hypercholesterolemic rabbits were 
diminished in a subgroup of animals lacking a functional thromboxane receptor (15).  
These previous results suggest that a contributing mechanism underlying alterations to 
vascular reactivity under conditions of hypercholesterolemia may involve both elevated 
vascular oxidant stress and metabolism of arachidonic acid through cyclooxygenase 
pathways.  However, given recent observations in our laboratory (22) and by others (25) 
suggesting that alterations to endothelium-dependent reactivity may reflect the specific 
challenge imposed rather than a global impairment, we examined alterations to dilator 
reactivity in response to direct challenge with arachidonic acid itself, wherein the 
57
bioavailability of endothelium-derived nitric oxide is not a significant contributing element to 
the net mechanical response.  Using both apolipoprotein E and LDL receptor gene deletion 
mouse models of hypercholesterolemia, the hypothesis tested in the present study was 
that arachidonic acid-induced dilator reactivity of skeletal muscle arterioles would be 
impaired in the presence of profound dyslipidemia and that this would be the result of 
alterations to either the production or vascular reactivity to metabolites of arachidonic acid 
via cyclooxygenase, owing to the presence of an elevated oxidant stress.   
MATERIALS AND METHODS 
Animals:  The present study used three strains of mice, the C57/Bl/6J (C57) as the control 
strain and the apolipoprotein E gene deletion (B6.129P2-Apoetm1Unc/J; ApoE) and low 
density lipoprotein receptor gene deletion (B6.129S7-Ldlrtm1Her/J; LDLR) mice on the 
C57/Bl/6J background.  All mice were purchased from Jackson Laboratories (Bar 
Harbor, ME) at 6 weeks of age.  The ApoE mouse manifests type III hyperlipidemia, in 
which both plasma cholesterol and triglyceride levels are elevated, although the 
elevations in LDL are not as severe as in the LDLR gene deletion mouse (19). In 
contrast, the LDLR mouse is a model of human familial hypercholesterolemia, 
manifesting a profound increase in serum LDL levels while ingesting a normal diet (11). 
 Male mice of each strain were fed standard chow and drinking water ad libitum and 
were housed in an AAALAC-accredited animal care facility at the West Virginia University 
Health Sciences Center and all protocols received prior IACUC approval.  At 20 weeks of 
age, after an overnight fast, mice were anesthetized with injections of sodium pentobarbital 
(50 mg•kg-1 i.p.), and received tracheal intubation to facilitate maintenance of a patent 
airway.  In all mice, a carotid artery was cannulated for determination of arterial pressure.  
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Blood aliquots were drawn from the jugular vein cannula for determination of glucose and 
insulin (Linco), a lipid profile (Waco), and nitrotyrosine (Oxis).   
Preparation of Isolated Skeletal Muscle Resistance Arterioles: In anesthetized 
mice, the intramuscular continuation of the right gracilis artery was removed and 
cannulated, as described previously (8).  These first order arterioles were extended to 
their approximate in situ length and were equilibrated at 80% of the animal's mean 
arterial pressure in order to approximate the in vivo intralumenal pressure experienced 
by the animal (13).  Following equilibration, arteriolar reactivity was evaluated in 
response to increasing concentrations of arachidonic acid (10-10 M – 10-6 M; Sigma).  
Additionally, in select experiments arteriolar reactivity was also evaluated in response to 
increasing concentrations of prostacyclin (PGI2; 10-10 M – 10-6 M; Biomol) or carbocyclic 
thromboxane A2 (TxA2; 10-10 M – 10-6 M; Cayman).   
 Removal of the arteriolar endothelium was accomplished by passing an air bolus 
through the perfusate line into the isolated microvessel, the efficacy of which was 
determined from a loss of all dilator reactivity in response to application of 10-6 M 
acetylcholine (8).  To assess the contribution of nitric oxide production or the generation 
of metabolites via cyclooxygenase as mediators of arteriolar reactivity, isolated vessels 
were treated with the nitric oxide synthase inhibitor L-NG-nitroarginine methyl ester (L-
NAME; 10-4 M for 45 minutes prior to agonist challenge; Sigma) or the cyclooxygenase 
antagonist indomethacin (INDO; 10-6 M for 60 minutes prior to agonist challenge; 
Sigma), respectively.  To determine the contribution of metabolites of arachidonic acid 
mediated via cytochrome P450 enzymes, vessels were treated with the suicide 
substrate inhibitor 17-octadecynoic acid (17-ODYA; 10-5 M for 60 minutes prior to 
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agonist challenge; Sigma).  Previous studies have demonstrated that 17-ODYA 
profoundly attenuates both the ω-hydroxylation (producing 20-hydroxyeicosatetraenoic 
acid; 20-HETE) and epoxygenation (producing epoxyeicosatrienoic acids; EETs) 
reactions of arachidonic acid through cytochrome P450 (24), thus preventing changes 
to vascular levels of 20-HETE or EETs as contributing mediators to endothelium-
dependent dilation.   To assess the contribution of lipoxygenase metabolites to the 
patterns of arteriolar dilation, vessels were treated with nordihydroguaiaretic acid 
(NDGA; 3×10-5 M for 45 minutes prior to agonist challenge; Biomol), a selective inhibitor 
of 12/15-lipoxygenases (20, 27).  To antagonize vascular PGH2/TxA2 receptors, vessels 
were treated with SQ-29548 (10-5 M for 30 minutes prior to agonist challenge; Biomol), 
while inhibition of thromboxane synthase was accomplished using carboxyheptyl 
imidazole (CHI; 10-5 M for 45 minutes prior to agonist challenge; Biomol).    To reduce 
vascular oxidant tone, arterioles were treated with 4-Hydroxy-2,2,6,6-
tetramethylpiperidine-1-15N-oxyl (TEMPOL; 10-4M for 60 minutes prior to agonist 
challenge, Sigma). 
Determination of Vascular Metabolites of Arachidonic Acid:  Vascular production of 6-
keto-prostaglandin F1α (6-keto-PGF1α; the stable breakdown product of PGI2; ref. 14), and 
11-dehydro-thromboxane B2 (11-dehydro-TxB2; the stable plasma breakdown product of 
TxA2; ref. 4) in response to challenge with arachidonic acid within the three mouse strains 
was assessed using pooled conduit arteries (femoral, saphenous, iliac, carotid arteries) 
from each mouse.  Vessels were incubated in microcentrifuge tubes in 1 ml of physiological 
salt solution for 30 minutes under control conditions (21% O2), after which time arachidonic 
acid (10-6 M) was added to the tube for an additional 30 minutes.  After the second 30 
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minute period, the PSS was transferred to a new tube, frozen in liquid N2 and stored at -
80°C.  Metabolite release by the vessels was determined using commercially available EIA 
kits for 6-keto-PGF1α and 11-dehydro-TxB2 (Cayman). 
Data and Statistical Analyses:  Active tone of individual arterioles at the equilibration 
pressure was calculated as (ΔD/Dmax)•100, where ΔD is the diameter increase from rest 
in response to Ca2+-free PSS, and Dmax is the maximum diameter measured at the 
equilibration pressure in Ca2+-free PSS.   
 Dilator responses of isolated arterioles following challenge with dilator agonists were 
fit with the three-parameter logistic equation: 
⎥⎦
⎤⎢⎣
⎡
+
−+= −xEDy 50log101
minmaxmin  
where y  represents the change in arteriolar diameter, “min” and “max” represent the lower 
and upper bounds, respectively, of the change in arteriolar diameter with increasing agonist 
concentration, x  is the logarithm of the agonist concentration and 50logED  represents the 
logarithm of the agonist concentration ( x ) at which the response ( y ) is halfway between 
the lower and upper bounds.     
 Data are presented as mean±SEM.  Statistically significant differences in measured 
and calculated parameters in the present study were determined using analysis of variance 
(ANOVA).  In all cases, Student-Newman-Keuls post hoc test was used when appropriate 
and p<0.05 was taken to reflect statistical significance.   
RESULTS 
 Table 1 presents baseline characteristics of the mouse groups in the present study.  
While all mice were of similar mass at 20 weeks of age, LDLR experienced a significant 
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elevation in mean arterial pressure and fasting insulin concentration versus values in C57 
or ApoE.   Additionally, both ApoE and LDLR manifested a profound hypercholesterolemia, 
most severe in LDLR.  Further, ApoE exhibited a significant hypertriglyceridemia as well, 
while plasma triglyceride levels in LDLR were not different from that in C57.  Finally, 
plasma levels of nitrotyrosine, a marker of chronic elevations in oxidant stress, were 
significantly elevated in ApoE and LDLR as compared to C57.  With regard to basal 
vascular tone, isolated arterioles from all mouse groups demonstrated a comparable 
resting active diameter and passive (calcium-free) diameter, such that no significant 
difference in active tone was calculated between C57, ApoE and LDLR in the present 
study. 
 Data summarizing the dilator responses of skeletal muscle resistance arterioles 
from C57, ApoE and LDLR in response to challenge with increasing concentrations of 
arachidonic acid are presented in Figure 1.  Under control conditions, the reactivity of 
arterioles from ApoE and LDLR, while not significantly different from each other, both 
demonstrated a reduction in their maximum bound as compared to responses in arterioles 
from C57.  Endothelium-denudation via perfusion with an air bolus eliminated mechanical 
responses of vessels across the three strains in response to application of arachidonic 
acid. 
 The effects of pharmacological blockade of lipoxygenases and cyclooxygenases 
with NDGA and INDO, respectively, on arachidonic acid-induced vasodilation in isolated 
arterioles are summarized in Figure 2.  In arterioles from C57 (Panel A), blockade of 
lipoxygenases with NDGA had no impact on dilator responses to arachidonic acid, while 
treatment with indomethacin abolished all dilation to arachidonic acid.  Arterioles from 
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ApoE, while demonstrating a blunted overall reactivity to arachidonic acid, also 
experienced a severe reduction in dilator reactivity following cyclooxygenase inhibition with 
indomethacin (Panel B).  However, while treatment with NDGA alone did not impact 
arachidonic acid-induced dilation in vessels from ApoE, application of NDGA to vessels 
that had been treated with indomethacin eliminated the residual dilation in response to 
arachidonic acid that remained following cyclooxygenase inhibition alone.  Finally, 
arterioles from LDLR appeared to demonstrate a dilator response to arachidonic acid 
challenge that was dependent on the production of metabolites generated via both 
lipoxygenases and cyclooxygenases, as antagonists to these pathways given in isolation 
resulted in modest reductions to the compromised level of reactivity, while treatment with 
both NDGA and indomethacin abolished all arachidonic acid-induced reactivity (Panel C).  
Treatment of isolated arterioles from C57, ApoE or LDLR with either L-NAME or 17-ODYA 
did not result in either significant or consistent effects of dilator responses following 
challenge with increasing concentrations of arachidonic acid (data not shown). 
 Figure 3 presents the effects of antagonizing thromboxane A2 generation (with CHI) 
and action (with SQ-29548) on dilator responses of skeletal muscle arterioles in the 
present study.  In control animals, application of either CHI or SQ-29548 had no impact on 
arteriolar dilation in response to increasing concentrations of arachidonic acid (Panel A).  In 
contrast, arterioles from both ApoE (Panel B) and LDLR (Panel C) exhibited a significant 
improvement to their degree of arachidonic acid-induced dilation relative to untreated 
conditions following either inhibition of thromboxane synthase with CHI or blockade of the 
PGH2/TxA2 receptor (SQ-29548). 
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  Data describing the arachidonic acid-induced generation of the cyclooxygenase 
products PGI2 (estimated from levels of 6-keto-PGF1α) and TxA2 (estimated from levels of 
11-dehydro TxB2) from pooled arteries of the three mouse groups in the present study are 
summarized in Figure 4.  Following application of 10-6 M arachidonic acid, arteries from 
C57, ApoE and LDLR all demonstrated a significant increase in PGI2 release, the degree of 
which was comparable between the three mouse strains (Panel A).  In contrast, 
arachidonic acid-induced generation of TxA2, while statistically significant in arteries from 
C57, demonstrated a substantially more robust response in vessels from both ApoE and 
LDLR (Panel B).  Pre-treatment of pooled vessels with either CHI or indomethacin severely 
attenuated all arachidonic acid-induced TxA2 generation in all three strains. 
 Arteriolar reactivity in response to challenge with prostacyclin (Panel A) or 
carbocyclic thromboxane A2 (Panel B) in the three mouse groups is summarized in Figure 
5.  In response to increasing concentrations of prostacyclin, arterioles from C57 and ApoE 
demonstrated a very similar degree of dilator reactivity, although this response 
demonstrated a trend toward impairment in vessels from LDLR as compared to that in 
vessels from either other strain (Panel A).  Arterioles from all three mouse strains exhibited 
very similar patterns of constrictor reactivity in response to challenge with increasing 
concentrations of carbocyclic thromboxane A2 (Panel B). 
 Figure 6 presents the effects of treating vessels with the antioxidant TEMPOL, the 
thromboxane synthase inhibitor CHI, or both, on arteriolar responses to increasing 
concentrations of arachidonic acid.  Addition of TEMPOL did not have a significant impact 
on arteriolar diameter in vessels from any of the three mouse strains under resting 
conditions.  In arterioles from C57 (Panel A), neither treatment with TEMPOL nor CHI had 
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a significant impact on dilator reactivity to arachidonic acid.  In contrast, for arterioles from 
both ApoE (Panel B) and LDLR (Panel C), treatment with either TEMPOL or CHI 
significantly improved dilator responses to arachidonic acid, with the effects of CHI being 
stronger than that for TEMPOL.  Interestingly, in both ApoE and LDLR, combined 
treatment with CHI and TEMPOL did not have any effect on arachidonic acid-induced 
dilation beyond that determined for CHI treatment alone.  
 Figure 7 presents data describing the effects of treating arteries from C57, ApoE or 
LDLR with TEMPOL on arachidonic acid-induced thromboxane A2 production.  While 
treatment with the antioxidant had an insignificant impact on vascular thromboxane 
production in C57, incubation of vessels with TEMPOL significantly reduced the 
arachidonic acid-induced production of TxA2 in both ApoE and LDLR.  However, this 
reduction in thromboxane generation was only partial in nature, and levels of TxA2 
production in response to challenge with arachidonic acid following treatment with 
TEMPOL remained significantly increased versus that in untreated arteries from ApoE and 
LDLR.  
DISCUSSION 
 Although hypercholesterolemia represents a powerful risk factor for the 
development of peripheral artery disease (1), the effects of hypercholesterolemia on 
vascular reactivity and endothelial function is less clearly understood.  Given recent studies 
suggesting that diet-induced hypercholesterolemia can alter arachidonic acid metabolism 
and profoundly impact vascular reactivity through signaling mechanisms associated with 
the generation of thromboxane A2 (15, 18, 21), the present study determined the effects of 
genetic hypercholesterolemia on the dilator reactivity of skeletal muscle resistance 
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arterioles in response to challenge with arachidonic acid.  More specifically, the hypothesis 
tested in this study was that arachidonic acid-induced arteriolar dilation in ApoE and LDLR 
would be impaired owing to either the production of, or vascular reactivity to, metabolites of 
arachidonic acid via cyclooxygenase, and that these alterations would be associated with 
an elevated oxidant stress. 
 Contrary to our results with dilator stimuli that are more strongly dependent on the 
bioavailability of endothelium-derived nitric oxide, where reactivity was largely maintained in 
the face of a profound reduction in this parameter (22), the results presented in Figure 1 
indicate that skeletal muscle arteriolar dilation in response to increasing concentrations of 
arachidonic acid was significantly reduced in both ApoE and LDLR as compared to 
responses determined in C57.  Interestingly, the data presented in this figure also strongly 
suggest that not only is the overwhelming majority of dilator reactivity in response to 
arachidonic acid dependent on a functional endothelium in control animals, the 
impairments to arteriolar dilation with this stimulus may also originate with alterations to 
endothelial function, rather than within vascular smooth muscle.   
 While results from the present study did not demonstrate a role for either nitric oxide 
bioavailability or for metabolites of arachidonic acid mediated via cytochrome P450 
enzymes in terms of contributing to the arachidonic acid-induced dilator reactivity of 
skeletal muscle arterioles in any of the three mouse strains, activity mediated through 
cyclooxygenase (and to a lesser extent lipoxygenase) were critical.  While arteriolar dilation 
in response to arachidonic acid was mediated entirely via cyclooxygenase in vessels from 
C57, vessels from ApoE and LDLR demonstrated a dilator response that was increasingly 
a function of metabolites via both cyclooxygenase and lipoxygenase, with this effect being 
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more pronounced in LDLR than in ApoE, where the response was still predominantly 
cyclooxygenase-dependent.  However, the data presented in Figure 2 do not provide 
significant insight into the impaired dilator reactivity demonstrated in arterioles of ApoE and 
LDLR in response to challenge with arachidonic acid beyond the critical involvement of 
cyclooxygenase.  Given previous studies suggesting that the development of the 
hypercholesterolemic condition can profoundly impact arachidonic acid metabolism in 
general (7, 18), and the recent studies from both Pfister (15) and Srisawat et al. (21) that 
implicate altered behavior mediated through thromboxane generation/action as contributing 
mechanism to altered patterns of vascular reactivity with hypercholesterolemia, we treated 
vessels from ApoE and LDLR with an inhibitor of thromboxane synthase (CHI) or an 
antagonist for the PGH2/TxA2 receptor (SQ-29548).  As shown in Figure 3, while neither of 
these agents had a significant role in the dilator responses in arterioles from C57, 
application of either CHI or SQ-29548 resulted in a significant improvement in the dilator 
responses of arterioles from ApoE or LDLR in response to challenge with increasing 
concentrations of arachidonic acid.  Interestingly, the ameliorative effect was comparable 
with either pharmacological agent.  While this implicates either increased thromboxane 
generation or an increased gain/sensitivity at the vascular thromboxane receptor as 
contributing mechanisms to the impaired arachidonic acid-induced arteriolar dilation, these 
data do not provide insight into which component may be most responsible.  However, 
these data do strongly suggest that the development of a thromboxane-sensitive 
component which may act to constrain arachidonic acid-induced arteriolar dilation 
accompanies the evolution of genetic hypercholesterolemia. 
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 As both CHI and SQ-29548 elicited similar improvements to arteriolar dilation in 
response to arachidonic acid challenge in ApoE and LDLR, it was necessary to discern 
which processes contributed to the constrained dilator reactivity: 1) increasing 
thromboxane A2 production in response to arachidonic acid production, 2) increased 
vascular reactivity to produced thromboxane A2, or both.  The data presented in Figure 4 
indicate that arachidonic acid-induced generation of PGI2 (estimated from 6-keto-PGF1α 
levels) remained intact in arteries of ApoE and LDLR as compared to that determined in 
C57, an observation that is consistent with previous studies in the coronary vasculature of 
ApoE mice (9).  In contrast, arachidonic-acid induced generation of thromboxane A2 
(estimated from 11-dehydro-TxB2 levels) was significantly increased with the evolution of 
genetic hypercholesterolemia in ApoE and LDLR.  When taken together with data in Figure 
5, which suggest that the sensitivity of resistance arterioles from ApoE and LDLR in 
response to increasing concentrations of either prostacyclin or thromboxane A2 is not 
dramatically altered from that determined for C57 control mice, these data may provide 
compelling evidence that a predominant contributing mechanism underlying the 
constrained arteriolar dilation with increasing concentrations of arachidonic acid may be the 
development of an increased generation of the constrictor prostanoid thromboxane A2, 
which antagonizes the dilator effects associated with the generation of prostacyclin. 
 Given that previous studies have clearly demonstrated the critical role for elevated 
oxidant tone in the increased generation of thromboxane through cyclooxygenase in 
response to challenge with arachidonic acid (2, 28, 29), and our observations of an 
increase in the plasma levels of nitrotyrosine in the ApoE and LDLR as compared to that 
determined in C57, the data presented in Figures 6 and 7 provide some insight into the 
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potential role that elevated vascular oxidant tone may play in the increased arachidonic 
acid-induced thromboxane A2 generation with genetic dyslipidemia.  While treatment with 
TEMPOL had no impact on arachidonic acid-induced dilation or TxA2 generation in 
arterioles from C57, it significantly improved the dilator response in microvessels from both 
ApoE and LDLR and reduced the levels of TxA2 production.  However, in vessels from both 
strains, this improvement in dilator reactivity following treatment with the antioxidant was 
less pronounced than that determined following treatment with the inhibitor of thromboxane 
synthase, CHI.  Further, combined treatment with both TEMPOL and CHI did not result in 
an improvement beyond that determined with CHI treatment alone.  Additionally, while pre-
treatment of pooled vessels with TEMPOL lowered arterial thromboxane production in 
response to challenge with arachidonic acid, the levels of thromboxane production 
remained significantly elevated despite the addition of the antioxidant.  Taken together 
these results suggest that, while an enhanced arachidonic acid-induced genesis of 
thromboxane A2 via thromboxane synthase represents a strong contributor to the 
constrained dilator reactivity in skeletal muscle arterioles of ApoE and LDLR mice, the 
presence of an elevated vascular oxidant tone may represent a partial contributor to this 
shift in the metabolism of arachidonic acid.  Clearly, these results suggest that other 
parameters, independent of acute changes in vascular oxidant tone, also contribute to this 
increased generation of thromboxane A2.  Potential avenues for ongoing investigation in 
this regard can include the study of not only the effects of chronic elevations in vascular 
oxidant tone, but also the progression of a chronic state of inflammation associated with 
dyslipidemia (10, 26) and how these processes can ultimately impact pathways of 
arachidonic acid metabolism. 
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 In summary, with the development of genetic hypercholesterolemia in ApoE and 
LDLR mice, the dilator reactivity of skeletal muscle resistance arterioles in response to 
increasing concentrations of arachidonic acid is impaired.  This impairment does not 
appear to be associated with a reduction in the generation/release of, or an altered 
arteriolar reactivity to, prostacyclin.   However, with the evolution of this dyslipidemic 
condition, there appears to be an increase in the arachidonic acid-induced generation of 
the vasoconstrictor metabolite thromboxane A2.  While there does not appear to be an 
alteration to the arteriolar constrictor reactivity to thromboxane, the increased generation of 
this metabolite may compete with the dilator effects of prostacyclin, thus limiting net dilator 
reactivity in response to arachidonic acid.  Further, while an increase in vascular oxidant 
stress appears to contribute to this response, additional mechanisms which are 
independent of acute alterations to oxidant tone also contribute to this effect.    Future 
investigation will be required to discern which mechanistic alterations associated with the 
development of hypercholesterolemia contribute to the increased production of 
thromboxane A2, and what the implications of this shift in the metabolism of arachidonic 
acid are for issues such as the integrated control of tissue perfusion, tissue oxygenation 
and the protection from atherogenesis and atherothrombosis. 
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Table 1.  Baseline characteristics of mice and individual arterioles used in the present 
study.  * p<0.05 vs. C57; † p<0.05 vs. ApoE.      
 
 
 C57 ApoE  LDLR  
Mass (g) 33±2 34±2 33±2 
MAP (mmHg) 88±4 92±3 106±5*† 
[Glucose]blood (mg/dl) 84±7 103±11 115±7* 
[Insulin]plasma (ng/ml) 1.1±0.3 1.6±0.3 2.8±0.5* 
[Total Cholesterol]plasma (mg/dl) 88±9 288±17* 364±22*† 
[LDL Cholesterol]plasma (mg/dl) 49±5 260±11* 338±19*† 
[Triglycerides]plasma (mg/dl) 88±10 175±14* 116±18† 
Nitrotyrosineplasma (ng/ml) 14±5 54±11* 60±14* 
    
Inner Diameter – Active (μm) 54±4 55±5 51±4 
Inner Diameter – Passive (μm) 128±5 122±4 118±7 
Active Tone (%) 57±3 55±4 56±4 
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FIGURE LEGENDS 
Figure 1.  Data describing the dilator reactivity of isolated skeletal muscle resistance 
arterioles of C57, ApoE and LDLR mice in response to increasing concentrations of 
arachidonic acid.    Data, presented as mean±SEM, are shown for arterioles under control 
conditions and following removal of the vascular endothelium using air bolus perfusion 
(please see text for details).  n=6 animals for each strain; * p<0.05 vs. C57; † p<0.05 vs. 
control within that strain. 
 
Figure 2.  Data describing the dilator responses of isolated skeletal muscle resistance 
arterioles of C57 (Panel A), ApoE (Panel B) and LDLR (Panel C) mice in response to 
increasing concentrations of arachidonic acid.  Data, presented as mean±SEM, are shown 
for arterioles under control conditions, and following pharmacological inhibition of 
cyclooxygenases with indomethacin, lipoxygenases with NDGA or combined inhibition of 
both enzymatic pathways (please see text for details).  n=5-10 animals for each group; * 
p<0.05 vs. control conditions, † p<0.05 vs. no response. 
 
Figure 3.  Data describing the dilator responses of isolated skeletal muscle resistance 
arterioles of C57 (Panel A), ApoE (Panel B) and LDLR (Panel C) mice in response to 
increasing concentrations of arachidonic acid.  Data, presented as mean±SEM, are shown 
for arterioles under control conditions, and following pharmacological inhibition of 
PGH2/TxA2 receptors with SQ-29548 and thromboxane synthase with CHI (please see text 
for details).  n=6-7 animals for each group; * p<0.05 vs. control conditions. 
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Figure 4.  Data describing the arterial production of prostacyclin (as 6-keto-PGF1α; Panel 
A) or thromboxane A2 (as 11-dehydro TxB2; Panel B) from C57, ApoE and LDLR in 
response to 10-6 M arachidonic acid.  Data, presented as mean±SEM, are shown under 
control conditions, and following pharmacological inhibition of cyclooxygenase with 
indomethacin or thromboxane synthase (with CHI), as appropriate.  n=8 animals for each 
group, with each n representing pooled arteries from an individual mouse; please see text 
for details.  * p<0.05 vs. respective control; † p<0.05 vs. C57 under that condition; ‡ vs. 
ApoE under that condition. 
 
Figure 5.  Data (mean±SEM) describing the reactivity of isolated skeletal muscle 
resistance arterioles of C57, ApoE and LDLR mice in response to increasing 
concentrations of prostacyclin (Panel A) or carbocyclic thromboxane A2 (Panel B).  n=6 
animals for each group, no significant differences were identified in the vascular reactivity 
in response to increasing concentrations of prostacyclin or thromboxane A2. 
 
Figure 6.  Data, presented as mean±SEM, describing the dilator responses of isolated 
skeletal muscle resistance arterioles of C57 (Panel A), ApoE (Panel B) and LDLR (Panel 
C) mice in response to increasing concentrations of arachidonic acid.  Data are shown for 
arterioles under control conditions, following treatment of vessels with the antioxidant 
TEMPOL, following pharmacological inhibition of thromboxane synthase with CHI, and 
following treatment with both TEMPOL and CHI.  n=8-10 animals for each group; * p<0.05 
vs. control conditions; † p<0.05 vs. treatment with TEMPOL alone. 
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Figure 7.  Data describing the arterial production of thromboxane A2 (as 11-dehydro TxB2; 
Panel B) from C57, ApoE and LDLR in response to 10-6 M arachidonic acid.  Data, 
presented as mean±SEM, are shown under control conditions, and following treatment of 
pooled arteries with the antioxidant TEMPOL (10-4 M).  n=6 animals for each group, with 
each n representing pooled arteries from an individual mouse; please see text for details.  * 
p<0.05 vs. within-strain/no arachidonic acid; † p<0.05 vs. within-strain/with arachidonic 
acid. 
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Figure 4. 
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Figure 5. 
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Figure 6. 
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Figure 7. 
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 ABSTRACT 
Object: The obese Zucker rat (OZR) model of the metabolic syndrome is partly 
characterized by moderate hypercholesterolemia in addition to other contributing co-
morbidities.  Previous results suggest that vascular dysfunction in OZR is associated 
with chronic reduction in vascular nitric oxide (NO) bioavailability and chronic 
inflammation, both frequently associated with hypercholesterolemia.  As such, we 
evaluated the impact of chronic cholesterol reducing therapy on the development of 
impaired skeletal muscle arteriolar reactivity and microvessel density in OZR and its 
impact on chronic inflammation and NO bioavailability.  Materials and Methods:  
Beginning at 7 weeks of age, male OZR were treated with gemfibrozil, probucol, 
atorvastatin or simvastatin (in chow) for 10 weeks.  Subsequently, plasma and vascular 
samples were collected for biochemical/molecular analyses, while arteriolar reactivity 
and microvessel network structure were assessed using established methodologies 
after 3, 6 and 10 weeks of drug therapy.  Results: All interventions were equally 
effective at reducing total cholesterol, although only the statins also blunted the 
progressive reductions to vascular NO bioavailability, evidenced by greater 
maintenance of acetylcholine-induced dilator responses, an attenuation of adrenergic 
constrictor reactivity, and an improvement in agonist-induced NO production.  
Comparably, while minimal improvements to arteriolar wall mechanics were identified 
with any of the interventions, chronic statin treatment reduced the rate of microvessel 
rarefaction in OZR.  Associated with these improvements was a striking statin-induced 
reduction in inflammation in OZR, such that numerous markers of inflammation were 
correlated with improved microvascular reactivity and density.  However, using 
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 multivariate discriminant analyses, plasma RANTES, IL-10, MCP-1 and TNF-α were 
determined to be the strongest contributors to differences between groups, although 
their relative importance varied with time.  Conclusions:  While the positive impact of 
chronic statin treatment on vascular outcomes in the metabolic syndrome are 
independent of changes to total cholesterol, and are more strongly associated with 
improvements to vascular NO bioavailability and attenuated inflammation, these results 
provide both a spatial and temporal framework for targeted investigation into 
mechanistic determinants of vasculopathy in the metabolic syndrome.    
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 INTRODUCTION 
 Arising from a chronic hyperphagia which originates due to non-functional leptin 
receptor gene and an impaired satiety reflex (5, 23), the obese Zucker rat (OZR) rapidly 
develops insulin resistance, hypertriglyceridemia and a moderate hypertension (43).  
Combined with the parallel creation of a pro-thrombotic, pro-oxidant and pro-inflammatory 
environment, OZR are considered to be an excellent model for the clinical condition termed 
the metabolic syndrome (47).  Associated with these systemic pathologies, we and others 
have defined numerous impairments to microvascular structure and function in OZR which 
negatively impact skeletal muscle perfusion, both under resting conditions (15, 18, 19), in 
response to elevated metabolic demand (18, 19, 50, 51), following recovery from vascular 
occlusion (15) and during hemorrhage (16).   Chronic treatment of the metabolic syndrome 
with exercise (13, 52) or of individual contributing elements through pharmacological 
intervention (10, 16, 17, 48) have resulted in improvements to microvascular outcomes, as 
well as to perfusion responses within skeletal muscle (13, 52), and have implicated 
potential mechanisms through which these improvements may be manifested.  Recently, 
results from our laboratory have suggested that the chronic reduction in vascular nitric 
oxide (NO) bioavailability that accompanies development of the metabolic syndrome in 
OZR is well correlated with the severity of the reduction in skeletal muscle microvessel 
density (16).  Ongoing studies have also suggested that while this microvascular 
rarefaction is hypertension-independent (17), exercise-based interventions that not only 
increase vascular NO bioavailability, but also blunt the severity of the chronic inflammatory 
state in OZR, may be an excellent predictor of the ability to prevent microvessel loss within 
the periphery (13). 
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  Within the metabolic syndrome in OZR is an elevation in plasma cholesterol levels 
that, while consistent, is more moderate as compared to the profound elevations 
determined for plasma triglycerides.  Given the severity of many indices of vascular 
dysfunction in OZR, the extent to which elevated plasma cholesterol contributes to these 
impairments in currently unclear.  However, treatment of hypercholesterolemia with 3-
hydroxy-3-methylglutaryl coenzyme A (HMG Co-A) reductase inhibitors (“statins”) has not 
only the well-documented impact of lowering circulating plasma LDL and total cholesterol 
levels (21, 35), but also has been identified as having the beneficial impacts of increasing 
vascular NO bioavailability (3, 34) and blunting plasma markers of chronic inflammation 
(11, 32, 35).  Notably, it has been suggested that improvements to vascular function in 
human subjects or animals afflicted with hypercholesterolemia may reflect these pleiotropic 
effects of statin therapy rather than the direct impact of anti-cholesterol therapy itself (3, 26, 
31).  However, the extent to which these reflect independent ameliorative effects or effects 
which are strongly correlated remains unclear. 
 The purpose of the present study was to determine the impact of chronic anti-
cholesterol therapy on the temporal development of impairments to microvascular reactivity 
and network structure in skeletal muscle of OZR manifesting the metabolic syndrome.  
Further, the present study also attempted to demonstrate differences in treatment 
effectiveness of more recently developed statin medications as compared to traditional 
anti-cholesterol medications that do not fall into this category.  The tested hypothesis was 
that chronic ingestion of anti-cholesterol therapies would better maintain microvascular 
structure and function in OZR, although the benefit of these effects would be due to 
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 improvements in vascular NO bioavailability and chronic inflammation, rather than effects 
on plasma cholesterol per se. 
MATERIALS AND METHODS 
Animals:  Male lean (LZR) and OZR (Harlan) fed standard chow and drinking water (see 
below) ad libitum were housed at the West Virginia University Health Sciences Center and 
all protocols received prior IACUC approval.   At 6-7 weeks of age, LZR and OZR were 
divided into five groups within each strain:  
1. control (maintained on normal chow)  
2. treatment with gemfibrozil [GEM; maintained on chow containing 50 mg/kg/d 
gemfibrozil, a fibric acid derivative and PPARα agonist (24)],  
3. treatment with probucol [PRO; maintained on chow containing 100 mg/kg/d probucol, 
an agent which increases fractional rate of LDL catabolism during cholesterol 
elimination.  While probucol has moderate anti-oxidant properties, these appear to be a 
function of the LDL reducing effects of the drug rather than direct anti-oxidant effects 
(24)]. 
4. treatment with simvastatin [SIM: maintained on chow containing 20 mg/kg/d 
simvastatin, a cholesterol lowering agent via potent inhibition of HMG Co-A reductase 
(24, 53), which also possesses anti-inflammatory properties associated with improved 
NO bioavailability (12, 26, 28)].  
5. treatment with atorvastatin [ATOR; maintained on chow containing 10 mg/kg/d 
atorvastatin, a cholesterol lowering agent via potent inhibition of HMG Co-A reductase 
(24, 53), which also possesses anti-inflammatory properties associated with improved 
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 NO bioavailability (4, 25)].  The primary difference between SIM and ATOR may be that 
SIM has a greater capacity to elevate HDL-C than ATOR (9, 24, 28).  
 Rats were maintained on each of these groups for 3-4 weeks, 6-7 weeks or 10-11 
weeks, at which time animals were used for experimentation (at 10, 13 and 17 weeks of 
age, respectively).  On the day of the experiment, following an 8 hour fasting period, rats 
were anesthetized with injections of sodium pentobarbital (50 mg/kg, i.p.), and received 
tracheal intubation to facilitate maintenance of a patent airway.  In all rats, a conduit artery 
was cannulated for determination of arterial pressure and for infusion of supplemental 
anesthetic and drugs, as necessary.  Blood samples were drawn from the cannula for 
determination of glucose and insulin concentrations (Linco) as well as cholesterol and 
triglyceride levels (Waco).  Plasma markers of inflammation were determined using 
commercially available ELISA systems (Luminex; Linco). 
Preparation of Isolated Skeletal Muscle Resistance Arterioles: In all rats, the 
intramuscular continuation of the right gracilis arteriole was removed and cannulated 
(19).  Within an individual group (above), vessels were divided into two sub-groups 
following an equilibration period.  Group 1 examined dilator responses, where arteriolar 
reactivity was evaluated in response to application of acetylcholine (10-10 M – 10-5 M) 
and sodium nitroprusside (10-6 M) to assess reactivity to NO from both endothelium-
dependent and independent agonists, respectively.  Subsequently, vessels were treated 
with TEMPOL (10-4 M) to assess the contribution of vascular oxidant tone to agonist-
induced dilation.  Group 2 examined constrictor reactivity, and mechanical responses 
were determined following challenge with phenylephrine (10-10 M – 10-7 M).  
Subsequently, vessels were treated with TEMPOL or L-NAME (10-4 M) to assess the 
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 contribution of vascular oxidant tone and endothelium-dependent NO production to the 
adrenergic constriction.   
 In all vessels, following the completion of the above procedures, the perfusate 
and superfusate were replaced with Ca2+-free PSS and vessels were treated with 10-7 M 
phenylephrine until all tone was abolished.  At this time, intralumenal pressure within the 
vessel was altered, in 20 mmHg increments, between 0 mmHg and 160 mmHg and the 
inner and outer diameter of arterioles was determined at each pressure.  These data 
were used to calculate arteriolar wall mechanics which were used as indicators of 
structural alterations to the microvessel wall (2, 20). 
Measurement of Vascular NO Bioavailability: From a cohort of rats within the oldest 
group (17 weeks of age), the abdominal aorta was removed and vascular NO 
production was assessed using amperometric sensors (World Precision Instruments).  
Briefly, aortae were isolated, sectioned longitudinally, pinned in a silastic coated dish 
and superfused with warmed (37°C) PSS equilibrated with 95% O2 and 5% CO2.  The 
NO sensor (ISO-NOPF 100) was placed in close apposition to the endothelial surface 
and a baseline level of current was obtained.  Subsequently, increasing concentrations 
of methacholine (10-10–10-6 M) were added to the bath and the changes in current were 
determined.  To verify that responses represented NO release, these procedures were 
repeated following treatment of the aortic strip with L-NAME (10-4 M).   
Histological Determination of Microvessel Density:  At the conclusion of all muscle 
perfusion protocols, the gastrocnemius muscle from the left leg was removed, rinsed in 
PSS and fixed in 0.25% formalin.  Muscles were embedded in paraffin and cut into 5 μm 
cross sections.  Sections were incubated with Griffonia simplicifolia I lectin (Sigma), for 
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 subsequent determination of microvessel density (20, 21).     
Analyses of eNOS Expression and Activity:  For determination of NOS expression, 
skeletal muscle arteries were homogenized and proteins within the homogenate were 
separated under denaturing conditions on an 8% SDS-polyacrilamide gel, after which 
proteins were transferred to a PVDF membrane and blocked.  Subsequently, blots were 
incubated with mouse anti-eNOS/NOS Type III mAb (BD Transduction Laboratories), 
washed and incubated with appropriate horseradish peroxidase conjugated secondary 
antibody.  GE Healthsciences ECL advance kits were used to visualize proteins.  
Additionally, in the oldest cohort of rats, the ascending and thoracic aorta, along with 
non-cannulated carotid, femoral, saphenous and iliac arteries were removed and frozen 
in liquid N2, for the subsequent determination of NOS activity using a commercially 
available kit (Cayman).  
Experimental Protocols:   Initially, the right gracilis muscle resistance arteriole was 
removed for the evaluation of vascular reactivity and passive mechanical characteristics of 
the vessel wall, described above.  Upon completion of these procedures, the right 
gastrocnemius muscle was removed, cleared of non-muscular tissue, and its mass was 
determined.  This muscle was then used for determination of microvessel density, as 
described above.  Finally, the contralateral gastrocnemius muscle was removed for tissue 
banking and the aortic and arterial segments were removed for assessment of NO 
bioavailability and eNOS expression/activity, described above. 
Data and Statistical Analyses:  Mechanical responses of aortic rings following challenge 
with acetylcholine or phenylephrine were fit with the three-parameter logistic equation: 
⎥⎦
⎤⎢⎣
⎡
+
−+= −xEDy 50log101
minmaxmin  
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 where y  represents the change in isometric tension, “min” and “max” represent the lower 
and upper bounds, respectively, of the change in arteriolar diameter with increasing agonist 
concentration, x  is the logarithm of the agonist concentration and 50logED  represents the 
logarithm of the agonist concentration ( x ) at which the response ( y ) is halfway between 
the lower and upper bounds.     
 Data are presented as mean±SEM.  Statistically significant differences in measured 
and calculated parameters in the present study were determined using analysis of variance 
(ANOVA).  In all cases, Student-Newman-Keuls post hoc test was used when appropriate 
and p<0.05 was taken to reflect statistical significance.  For analyses of inflammatory 
markers between groups, we employed discriminant techniques to eliminate the univariate 
nature of ANOVA and issues of independent variable co-linearity which minimizes the utility 
of regression techniques.  Discriminant analyses are based on canonical correlation to 
maximize differences between a priori identified experimental groups.  Multiple variables 
are arranged into structural equations based upon their ceteris paribus ability to 
distinguish those group differences.  These stepwise analyses result in a rank ordering 
of correlation coefficients in terms of their significance for the establishment of 
differences between groups.  These produce a series of algebraic functions which 
explain the differences between group centroids in the “x” dimension (Function 1), the 
“y” dimension (Function 2).  Each function explains a specific percentage of the 
variance between the group centroids. 
RESULTS 
 Table 1 presents basic characteristics of animal groups within the present study.   
OZR were consistently heavier than LZR, and this was not impacted by the anti-cholesterol 
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 therapies.   While OZR ultimately developed a moderate hypertension as compared to 
LZR, the development of the elevated blood pressure was attenuated in OZR-SIM and 
OZR-ATOR groups.  Fasting glucose was elevated in all OZR versus age matched LZR 
after 10 weeks of age, although glycemic control was improved in OZR-SIM and OZR-
ATOR groups, as the level of blood glucose was associated with reduced plasma insulin 
with increasing age.  The hypercholesterolemia in OZR was largely abolished as a result of 
the four anti-cholesterol therapies, and there was a modest blunting of the 
hypertriglyceridemia as a result of the PRO, SIM and ATOR treatments with age.  Finally, 
plasma levels of nitrotyrosine were elevated with age in OZR versus LZR, indicative of a 
chronic elevation in oxidant stress, and this difference was blunted by chronic treatment 
with probucol, simvastatin and atorvastatin.   
 The changes to skeletal muscle microvessel density with time in LZR and OZR, and 
the impact of chronic treatment with the anti-cholesterol agents are summarized in Figure 
1.  Microvessel density was not significantly impacted by the evolution of the metabolic 
syndrome at 7 weeks of age between LZR and OZR (Panel A), and as such, none of the 
pharmacological treatments impacted this relationship.  However, with increasing severity 
of the metabolic syndrome over time, the degree of microvascular rarefaction was 
increased between OZR and LZR (Panels B-D).  Chronic treatment with GEM and PRO 
had minor impacts on rarefaction in OZR, despite their effectiveness in reducing total 
cholesterol.  In contrast, chronic treatment with either SIM or ATOR was effective at 
delaying/blunting the progression of microvascular rarefaction in OZR at 10, 13 and 17 
weeks of age.   
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  At both 7 (Panel A) and 10 weeks (Panel B) of age, regardless of experimental 
group, both the arteriolar incremental distensibility and the circumferential stress versus 
strain relationship (panel inset) was not different between LZR and OZR (Figure 2).  
However, in both 13 week (Panel C) and 17 week (Panel D) old OZR, the slope coefficient 
describing this parameter was significantly elevated in OZR as compared to LZR under 
control conditions.  While the anti-cholesterol therapies did not significantly impact this shift 
in the stress versus strain relationship between arterioles of LZR and OZR at 13 weeks of 
age, treatment with SIM or ATOR blunted this difference at 17 weeks of age, such that the 
slope coefficients exhibited an intermediate phenotype between that for untreated LZR and 
OZR. 
  Data describing arteriolar dilation in response to challenge with acetylcholine and 
the impact of acute treatment of vessels with TEMPOL on the upper bound of this 
relationship are summarized in Figure 3.  At 7 weeks of age, the acetylcholine-induced 
dilator reactivity of resistance arterioles from LZR and OZR was comparable, regardless of 
experimental groups (Panel A) and the impact of anti-oxidant treatment on this response 
was negligible (Panel B).  A similar situation is present at 10 weeks of age, although 
separation in the acetylcholine-induced dilation of resistance arterioles, while not 
statistically significant between LZR and OZR, is becoming apparent (Panel C).  However, 
by 13 weeks of age (Panels E and F), and even more evident at 17 weeks of age (Panels 
G and H), acetylcholine-induced dilation was significantly reduced in OZR versus LZR, and 
this separation was blunted by treatment with SIM and ATOR.  The impact of TEMPOL 
treatment on this response also began to demonstrate differences, as treatment of 
arterioles from OZR and OZR-GEM with the anti-oxidant resulted in a significant 
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 improvement in the upper bound of the acetylcholine-induced response.  In all cases, 
treatment of vessels with L-NAME abolished arteriolar responses to acetylcholine, and 
arteriolar dilation in response to challenge with sodium nitroprusside was not different 
between groups (data not shown).   
 Regardless of the pharmacological intervention imposed, arterial expression of 
eNOS between LZR and OZR did not demonstrate a consistent or significant difference 
between or within the two strains.  Further, there was no evidence of a consistent or 
significant impact of age on eNOS expression between LZR and OZR (data not shown). 
 Figure 4 summarizes arterial eNOS activity and methacholine-induced NO 
production in the oldest cohort of LZR and OZR under the conditions of the present study.  
At 17 weeks of age, eNOS activity (Panel A) was not significantly different between LZR 
and OZR, and treatment with the anti-cholesterol therapies was without consistent effect.  
Additionally, methacholine-induced production of NO from arterial strips, assessed using 
amperometric sensors, was attenuated in OZR versus LZR (Panel B), although chronic 
ingestion of SIM or ATOR increased NO production in response to challenge with 
methacholine in OZR.   
 Data describing arteriolar constrictor responses in vessels from LZR and OZR 
following challenge with phenylephrine under the conditions of the present study are 
summarized in Figure 5.  At 7 (Panel A) and 10 (Panel C) weeks of age, challenge with 
increasing concentrations of phenylephrine produced similar arteriolar constrictor response 
in OZR versus LZR under control conditions, and this relationship was not impacted by any 
of the anti-cholesterol therapies.  Further, inhibition of eNOS enzymes with L-NAME had no 
impact on these responses at either 7 weeks (Panel B) or 10 weeks (Panel D) of age.  
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 However, by 13 weeks of age, OZR began to exhibit an increased constrictor response to 
phenylephrine (Panel E), and this effect was even more pronounced at 17 weeks of age 
(Panel G).  This increased constrictor response was largely unaltered by chronic treatment 
with GEM or PRO at either age, although chronic treatment with SIM and ATOR blunted 
the augmentation to phenylephrine-induced constriction with age in OZR.  Acute inhibition 
of eNOS with L-NAME had no effect on the differences in phenylephrine-induced 
constriction at 13 (Panel F) and 17 (Panel H) weeks of age between LZR and OZR under 
control conditions or following chronic treatment with GEM, but attenuated the impact of 
SIM and ATOR on moderating the increased adrenergic reactivity in OZR with age.  Acute 
application of phentolamine (10-5 M) abolished all arteriolar responses to phenylephrine 
(data not shown). 
 Data describing the changes in plasma markers of inflammation across groups are 
summarized in Table 2.   As compared to marker concentration in LZR, OZR demonstrated 
significant elevations in plasma concentrations of IL-1β, IL-6, IL-10, TNF-α, RANTES, 
MCP-1 and VEGF between 7 and 17 weeks of age.  In general, GEM treatment had a 
minimal impact on these relationships in OZR, regardless of animal age, and PRO 
treatment reduced the elevation in RANTES (regulated upon activation normal T-cell 
expressed and secreted) at 17 weeks only.  In contrast, treatment of OZR with SIM or 
ATOR altered levels of all markers by 13 weeks of age, except VEGF, such that their 
plasma concentration was significantly different from that in OZR under control conditions.  
Regardless of treatment, plasma concentrations of VEGF were elevated in OZR versus 
LZR.  
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  Figure 6 summarizes data from 17 week old animals from all experimental groups 
correlating gastrocnemius muscle microvessel density with plasma total cholesterol (Panel 
A) or vascular NO bioavailability (Panel B), with values from individual animals being 
presented.  As evident from Panel A, plasma total cholesterol is a poor predictor of 
rarefaction and does not effectively explain the variability in muscle vascularity in the 
present study.  In contrast, NO bioavailability, estimated from the magnitude of the upper 
bound from the three parameter logistic equation describing the acetylcholine 
concentration-response curve for individual arterioles, was a much stronger predictor of 
muscle vascularity, as this parameter explained almost 81% of the variability in vessel 
density in the present study.   This relationship is evident at other ages as well (data not 
shown). 
 Table 3 presents the results of stepwise discriminant analysis based on 
inflammatory marker data across the experimental groups.  These analyses suggest that, 
while most measured markers of inflammation were well correlated with microvessel 
density and NO bioavailability, IL-10 and MCP-1 were consistent contributors to differences 
not only across the experimental groups, but also over time within individual groups.  In 
contrast, plasma RANTES levels became increasingly significant with time in terms of 
discriminating between groups.  Alternatively, plasma TNF-α, demonstrated an inverse 
relationship, become less significant with time, to the point where it dropped out of the 
model entirely.  These data are presented graphically in Figure 7.  Plasma levels of VEGF, 
IL-6 and IL-1β, while well correlated with microvessel density based on univariate analyses 
did not contribute to the ability to discriminate between groups, and as such are not 
presented in Table 3.   
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  The relationships between these identified markers, NO bioavailability and 
microvessel density between 17 week old LZR and OZR is presented in Figure 8.  
RANTES (Panel A), IL-10 (Panel B), MCP-1 (Panel C), and TNF-α (Panel D) all 
demonstrate a strong correlation with NO bioavailability and microvessel density across the 
animal groups.   
DISCUSSION 
 As a contributing component to the metabolic syndrome, OZR develop moderate 
hypercholesterolemia, in addition to other co-morbidities associated with this multi-
pathology state.  While previous studies have suggested that elevated plasma cholesterol 
can be associated with reduced capillary density (7, 42) and blunted angiogenic responses 
(36, 45), it is presently unclear as to the contribution of inflammatory status in terms of 
mediating these effects.  Given this, the present study was designed to chronically treat 
OZR with multiple mechanistically distinct anti-cholesterol therapies throughout the period 
in which microvessel loss is established to better distinguish the role for plasma cholesterol 
in terms of its contribution to skeletal muscle microvascular rarefaction, and the role of 
chronic inflammation in this process.   
 The most immediate observation of the current study was that treatment of OZR 
with the anti-cholesterol agents all resulted in a comparable reduction in 
hypercholesterolemia at each age, despite mechanistically divergent routes of action.  
Probucol lowers cholesterol by increasing the fractional rate of LDL catabolism in the 
metabolic pathway for cholesterol elimination from the body, and may inhibit early 
stages of cholesterol biosynthesis (24).  Gemfibrozil, a fibric acid derivative, is a PPARα 
agonist and can reduce plasma LDL through multiple routes, including cholesteryl ester 
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 transfer protein activity, an increased binding affinity of LDL to its receptors, and an 
increased expression of hepatic LDL receptors (24).  Atorvastatin and simvastatin are 
HMG CoA reductase inhibitors, and as such exert their anti-cholesterol actions via an 
inhibition of this rate limiting step in cholesterol biosynthesis.  This inhibition of hepatic 
cholesterologenesis results in an increased expression of hepatic LDL receptors, and 
leads to lowered circulating cholesterol levels (24, 27).   
 Although each of these therapies was comparable in terms of efficacy in reducing 
plasma total cholesterol, considerable divergence was evident for their ability to 
ameliorate microvascular rarefaction and improve arteriolar reactivity.  From a structural 
perspective, despite reductions in total cholesterol, treatment with gemfibrozil (and to a 
lesser extent probucol) had a minimal impact on blunting microvascular rarefaction with 
age in OZR.  In contrast, chronic statin therapy lessened the severity of rarefaction, 
such that microvessel density assumed a level that, although reduced from LZR, was 
consistently improved versus untreated OZR.  This observation is intriguing in that 
recent studies have identified a biphasic, lipid-independent, effect of chronic statin 
therapy on microvessel density.  Specifically, it may be that low-dose statin therapy is 
associated with a “pro-angiogenic” environment through activation of Akt and increased 
NO bioavailability, whereas higher statin doses can cause angiostatic effects which are 
potentially mediated through a decreased protein prenylation and an inhibition of cell 
growth (4, 37, 39, 49).  With regard to mechanics of the microvessel wall in OZR, an 
ameliorative effect was also identified, as the severe reduction in wall distensibility in 
OZR was modestly attenuated as a result of chronic ingestion of atorvastatin or 
simvastatin, with lesser impacts from probucol or gemfibrozil.  These results support 
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 those determined previously, as statin therapy has been effective in reducing wall 
stiffness in hypercholesterolemia (38, 40), although additional studies have suggested 
that this effect may be independent of lipid profiles (44), and may better represent the 
pleiotropic effects of statins on endothelial function or inflammatory status.   
 In our previous studies, we have provided evidence suggesting one of the main 
causative mechanisms associated with microvascular rarefaction in OZR may be a 
chronic reduction in vascular NO bioavailability (16).  The present results support this 
hypothesis, as both vascular reactivity to acetylcholine (Figure 3) and methacholine-
induced NO production (Figure 4) were improved with statin therapy in OZR.  Further, 
when data from an age cohort of animals are summarized, an index of vascular NO 
bioavailability (upper bound of the acetylcholine concentration-dilator response 
relationship) was a strong predictor of gastrocnemius muscle microvessel density 
(Figure 6).   
 The increased vascular NO bioavailability as a result of chronic atorvastatin or 
simvastatin treatment was also evident with regard to phenylephrine-induced constrictor 
reactivity.  Specifically, the increased constrictor response of arterioles of OZR (versus 
LZR) in response to adrenergic stimulation was not impacted by chronic anti-cholesterol 
therapy with gemfibrozil.  However, chronic treatment of OZR with atorvastatin, simvastatin 
or probucol blunted the upper bound of this response, although responses were still 
increased versus those in LZR.  This may have been due to an increased vascular NO 
bioavailability, as acute application of L-NAME, while having minimal impact on 
phenylephrine-induced arteriolar constriction in OZR (±gemfibrozil), increased the upper 
bound of this relationship in OZR treated with either of the other three agents.    These data 
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 clearly suggest that chronic treatment with anti-cholesterol agents of the “statin” family will 
increase the vascular NO bioavailability (and reduce vascular oxidant stress) in OZR, and 
that this relationship can impact both vascular reactivity (both dilator and constrictor) and 
microvascular network structure. 
 One of the profound implications for hypercholesterolemia is the genesis of an 
elevated state of inflammation (8, 29, 30), that can be associated with evolution of 
peripheral vasculopathy (34, 41, 46).  While inherent in the treatment of 
hypercholesterolemia is a reduction of plasma cholesterol, amelioration of inflammation, 
and improved outcomes, a key observation from the present study was that although each 
treatment was effective in reducing cholesterol in OZR, there was a considerable disparity 
in terms of these other processes.  In the OZR model of the metabolic syndrome, we (13) 
and others (1, 33) have clearly demonstrated an elevated state of inflammation and that 
specific markers of inflammation can be strongly correlated with vascular outcomes 
(positively or negatively, depending on marker and outcome).  As the metabolic syndrome 
is, by definition, composed of multiple pro-inflammatory pathologies (8), changes in 
multiple markers of inflammation between groups were each significant (Table 2).  Further, 
given that indices of microvascular dysfunction were also tightly associated with animal 
group, as well as NO bioavailability and inflammatory state severity, significant correlations 
were also determined between individual markers of inflammation and specific indices of 
vascular dysfunction.   While interesting from a conceptual standpoint, these results are 
largely uninformative with respect to evaluating mechanistic bases of inflammation-induced 
vascular dysfunction in OZR.  Further, additional insight cannot effectively be gleaned from 
multivariate regression techniques, as the independent variables (i.e., markers of 
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 inflammation) demonstrate a greater co-linearity amongst themselves than with an 
outcome (e.g., microvessel density). 
 As a result, we incorporated the use of discriminant analyses (Figure 7 and Table 
3), a classification technique for evaluating how multiple variables contribute to 
differences between experimental groups and one which is specifically designed for 
accurate hypothesis development.  These analyses result in a rank ordering of ceteris 
paribus correlation coefficients in terms of significance for the establishment of 
differences between groups.  The beneficial impact of discriminant analyses is that 
through a series of iterations, we are able to identify which parameters are most 
significant, and also which parameters are significant only because they operate 
through the magnitude of others.  As an example, while results from ANOVA or 
regression suggest that IL-1β or IL-6 are correlated with low NO bioavailability, they 
suffer from considerably co-linearity with other predictive markers, limiting their utility.  In 
contrast, discriminant analyses suggests that these markers may be less important than 
RANTES, MCP-1, IL-10, and TNF-α, and may not directly contribute to differences 
between LZR and OZR under control conditions and following chronic anti-cholesterol 
therapy.  These parameters identified from discriminant analyses can be used for the 
more targeted model development and future hypothesis testing.  It is important to 
emphasize that these procedures do not result in an identification of the four key 
markers contributing to vasculopathy in the metabolic syndrome.  Rather, given the 
limited data set employed in the present study, these analyses indicate how four 
markers, each of which demonstrates a strong univariate association with the vascular 
outcomes vary over time in terms of their ability to discriminate an outcome between 
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 experimental groups.  With ongoing study and the inclusion of additional discriminating 
elements, the results of these procedures will change, although the ultimate goal is the 
convergence on a more stable predictive model with increasing iterations. 
 One of the interesting observations of the present study was while chronic 
treatment with the anti-cholesterol agents reduced total cholesterol in OZR to levels that 
were comparable to that in LZR, treatment with either of the two statin medications had 
the additional benefit of also reducing mean arterial pressure and improving glycemic 
control (i.e., insulin sensitivity) as well as providing a modest lowering of the 
hypertriglyceridemia in OZR.  Given that the statin medications were also the most 
effective in terms of improving microvascular outcomes in the present study, it may be 
that the combination of these associated beneficial impacts of statin therapy on the 
other contributing pathologies of the metabolic syndrome in OZR also represented 
substantial mediators of the improvement to microvascular function.   While an 
appealing possibility, the current data only allow for speculation on this hypothesis, as 
additional control experiments would be required to evaluate the role for these additional 
elements.  However, this is an area of investigation that may warrant additional 
investment.   
 In summary, while development of moderate hypercholesterolemia in OZR is 
associated with impaired microvascular function, chronic treatment of elevated 
cholesterol levels does not per se result in a significant improvement to poor outcomes.  
Rather, only anti-cholesterol treatments that improved vascular NO bioavailability and 
attenuated the chronic inflammation in OZR (statins) were successful in improving 
microvascular and perfusion outcomes, suggesting that total plasma cholesterol itself 
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 may be a poor predictor of vascular outcomes in this model.  Chronic inflammation, 
when combined with vascular NO bioavailability, may be far stronger than total 
cholesterol as a predictor of vascular dysfunction, and the implementation of 
discriminant analyses for changes to the inflammatory profile may reflect a more 
informative means through which future experiments may be designed. 
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 Table 1.  Characteristics of animal groups within the present study.  * p<0.05 vs. LZR; † 
p<0.05 vs. OZR. 
 Age LZR OZR OZR-GEM OZR-PRO OZR-SIM OZR-ATOR 
Mass (g) 7w 155±5 241±6* 254±8* 250±9* 247±8* 245±5* 
 10w 238±6 401±8* 398±7* 400±9* 405±8* 408±7* 
 13w 304±7 513±10* 520±10* 508±12* 506±9* 501±8* 
 17w 369±5 628±12* 630±12* 625±13* 622±12* 618±9* 
MAP (mmHg) 7w 98±4 95±5 97±5 98±6 93±5 99±4 
 10w 99±5 99±5 102±6 100±5 99±4 100±5 
 13w 102±5 112±6 115±6 112±8 102±6 104±6 
 17w 102±4 129±5* 127±5* 123±4* 118±4* 113±5*† 
Glucose (mg/dl) 7w 93±7 98±4 104±7 102±8 96±8 93±6 
 10w 96±6 103±7 105±8 104±9 101±9 105±8 
 13w 99±7 123±8* 128±8* 128±8* 128±6* 121±8* 
 17w 106±9 168±10* 170±8* 169±11* 150±7* 155±8* 
Insulin (ng/ml) 7w 1.0±0.3 3.2±0.5* 4.1±0.6* 3.6±0.7* 2.9±0.5* 3.0±0.6* 
 10w 1.1±0.2 4.9±0.7* 5.4±0.6* 6.0±0.6* 4.8±0.6* 4.3±0.5* 
 13w 1.2±0.3 7.9±0.6* 7.5±0.7* 7.8±0.8* 6.0±0.6* 5.7±0.6* 
 17w 1.2±0.2 9.0±0.8* 8.2±0.6* 9.1±0.9* 6.4±0.8*† 6.5±0.6*† 
Chol (mg/dl) 7w 80±7 98±8 95±10 95±9 91±9 94±6 
 10w 82±6 106±7* 84±8† 83±9† 83±8† 84±7† 
 13w 77±8 128±10* 87±9† 88±9† 85±9† 85±9† 
 17w 71±10 142±12* 86±9† 84±11† 82±11† 81±12† 
TG (mg/dl) 7w 101±8 175±9* 178±12* 176±10* 180±11* 176±11* 
 10w 106±7 247±11* 249±14* 255±14* 252±12* 258±14* 
 13w 124±10 341±12* 338±11* 338±13* 290±14*† 302±13*† 
 17w 140±12 360±15* 342±20* 330±14*† 320±15*† 316±16*† 
N-tyrosine (ng/ml) 7w 9±2 16±4 17±4 12±4 13±4 14±3 
 10w 11±3 25±4* 26±4* 20±3* 16±4 15±5 
 13w 12±3 49±7* 45±7* 30±6*† 24±5* 25±4*† 
 17w 12±3 61±6* 53±5* 40±5*† 29±5*† 27±5*† 
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 Table 2.  Plasma markers of inflammation (pg/ml) in the present study.  * p<0.05 vs. LZR; 
† p<0.05 vs. OZR. 
 Age LZR OZR OZR-GEM OZR-PRO OZR-SIM OZR-ATOR 
IL-1β 7w 9.2±0.7 9.4±0.6 9.1±0.8 8.5±1.0 8.5±0.8 8.4±0.5 
 10w 9.4±0.6 13.4±1.8* 12.2±1.6* 12.6±1.8* 11.0±1.4* 10.8±1.1* 
 13w 9.8±0.7 18.5±2.0* 18.3±1.9* 16.8±1.7* 12.0±1.9*† 12.2±1.8*† 
 17w 10.2±0.8 23.2±2.5* 19.8±2.2* 18.5±2.0* 14.4±1.8† 15.0±2.0† 
IL-6 7w 26.2±4.8 35.5±5.1 33.8±4.6 29.8±5.3 28.0±4.5 31.1±4.4 
 10w 30.8±5.4 40.5±5.4 36.2±6.0 34.3±5.5 29.9±4.3 35.0±5.1 
 13w 36.8±5.6 68.6±6.1* 65.2±5.6* 64.6±5.8* 38.4±6.1† 40.6±4.6† 
 17w 38.6±4.6 79.8±5.7* 77.2±6.6* 71.0±6.4* 52.4±5.8† 53.9±6.1† 
IL-10 7w 14.6±2.6 24.8±4.0 22.0±4.1 16.5±3.8 15.2±3.8 14.6±3.1 
 10w 15.2±3.6 80.3±6.7* 75.3±8.0* 64.4±9.0* 51.0±6.8*† 49.5±5.8† 
 13w 16.4±3.7 116.4±10.5* 108.8±10.4* 104.3±8.9* 68.5±7.6*† 62.4±6.8*† 
 17w 18.4±3.0 124±11.5* 117.4±10.4* 114.4±12.0* 74.4±9.4*† 68.8±11.2*† 
TNF-α 7w 2.0±0.4 5.0±1.0* 5.1±0.9* 4.6±0.7* 3.9±0.7* 3.5±0.6* 
 10w 2.5±0.4 8.9±1.0* 8.4±1.1* 7.2±1.2* 5.8±0.8*† 6.3±1.1*† 
 13w 3.2±0.3 10.3±1.6* 9.8±0.9* 8.6±1.8* 5.0±1.2† 5.7±1.6† 
 17w 3.4±0.4 10.4±1.4* 10.8±1.2* 8.8±1.5* 6.2±1.4† 6.8±1.6† 
RANTES 7w 28.0±4.7 34.2±4.8 35.0±5.1 33.4±4.9 31.3±5.5 29.6±4.6 
 10w 32.2±4.6 66.6±7.9* 60.4±8.2* 53.4±5.3* 43.4±5.8† 44.2±4.7† 
 13w 36.4±4.8 120.2±10.3* 117.4±9.9* 108.8±10.9* 85.4±9.9*† 80.8±7.9*† 
 17w 40.1±5.3 187.2±14.1* 176.8±15.8* 138.4±14.8*† 97.8±14.0*† 102.8±13.6*† 
MCP-1 7w 36.6±5.8 45.0±5.9 43.8±5.2 45.6±4.9 40.4±5.1 41.2±6.0 
 10w 36.8±4.7 57.7±10.5 54.9±12.0 51.5±6.4 43.6±5.2*† 42.5±5.0* 
 13w 42.1±4.6 98.4±10.4* 95.6±10.6* 81.0±8.9* 66.4±9.4*† 62.2±6.3*† 
 17w 42.2±5.8 120.2±10.8* 118.4±12.0* 116.6±14.2* 80.4±12.1*† 77.8±11.4*† 
VEGF 7w 35.6±5.0 39.6±6.1 37.0±4.6 40.2±4.5 38.3±4.3 39.6±5.3 
 10w 41.1±5.3 55.5±4.5* 56.2±4.8* 50.2±5.3* 53.4±4.9* 55.5±4.5* 
 13w 39.2±5.3 62.9±6.7* 60.6±5.7* 58.6±6.1* 54.6±5.1* 56.9±6.4* 
 17w 38.9±4.1 68.7±5.4* 66.2±6.1* 61.8±5.8* 57.4±4.5* 58.8±4.8* 
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Table 3.  Structure matrix of results from discriminant analyses for markers of 
inflammation between animal groups in the present study.  * represents the largest 
absolute correlation between each variable and any discriminant function. 
Age 7 Weeks 10 Weeks 13 Weeks 17 Weeks 
Functions 1 2 1 2 1 2 1 2 
% of Variance 81.7 12.0 96.2 2.6 97.3 3.0 98.3 1.5 
Canonical Correlation 0.907 0.636 0.975 0.581 0.988 0.746 0.964 0.405 
RANTES --- --- 0.364 0.683* 0.504 0.289 0.647* -0.760* 
IL-10 0.390 0.700* 0.531* -0.182 0.576* -0.389 0.521 0.593 
MCP-1 0.368 -0.049 0.384 0.428 0.465 0.568* 0.501 0.452 
TNF-α 0.553* -0.568 0.401 -0.173 0.244 -0.300 --- --- 
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 FIGURE LEGENDS 
Figure 1.  Data (mean±SEM) microvessel density within skeletal muscle of LZR and OZR 
at 7 weeks (Panel A), 10 weeks (Panel B), 13 weeks (Panel C) and 17 weeks (Panel D) of 
age.  Microvessel density data are presented under control conditions and following 
chronic treatment of OZR with the anti-cholesterol therapies: gemfibrozil, probucol, 
simvastatin or atorvastatin.  Microvessel density was determined using fluorescence 
microscopy following labeling of microvessel with Griffonia simplicifolia I lectin (please see 
text for details).  * p<0.05 vs. LZR; † p<0.05 vs. OZR. 
 
Figure 2.  Data (mean±SEM) describing incremental distensibility and the slope (β) 
coefficients from circumferential stress versus strain relationships (inset panels) of skeletal 
muscle arterioles of LZR and OZR at 7 weeks (Panel A), 10 weeks (Panel B), 13 weeks 
(Panel C) and 17 weeks (Panel D) of age.   Arteriolar wall mechanics data are presented 
control conditions and following chronic treatment of OZR with the anti-cholesterol 
therapies: gemfibrozil, probucol, simvastatin or atorvastatin.  * p<0.05 vs. LZR; † p<0.05 
vs. OZR. 
 
Figure 3.  Data (mean±SEM) describing skeletal muscle arteriolar dilation in response to 
increasing concentrations of acetylcholine of LZR and OZR under control conditions and 
following chronic treatment of OZR with gemfibrozil, probucol, simvastatin or atorvastatin.  
Data area presented as paired panels, with the left panels summarizing the concentration-
response relationship, and the right panel presenting the contribution of oxidant stress in 
terms of impacting acetylcholine-induced dilation where the change in the upper bound of 
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 this relationship is shown following treatment of the arteriole with TEMPOL.  Data are 
presented for animals at 7 weeks (Panels A/B), 10 weeks (Panels C/D), 13 weeks (Panels 
E/F) and 17 weeks (Panels G/H) of age.  * p<0.05 vs. LZR; † p<0.05 vs. OZR.    
 
Figure 4. Vascular eNOS activity (Panel A; presented as the % arginine conversion), and 
methacholine-induced NO bioavailability (Panel B; where data present the slope of the 
relationship between vascular NO production and methacholine concentration , nM/log M 
methacholine) in LZR and OZR at 17 weeks of age.  Data (presented as mean±SEM) are 
summarized for LZR and OZR under control conditions and following chronic treatment of 
OZR with gemfibrozil, probucol, simvastatin or atorvastatin.    * p<0.05 vs. LZR; † p<0.05 
vs. OZR. 
 
Figure 5.   Data (mean±SEM) describing skeletal muscle arteriolar constriction in response 
to increasing concentrations of phenylephrine in LZR and OZR under control conditions 
and following chronic treatment of OZR with gemfibrozil, probucol, simvastatin or 
atorvastatin.  Data area presented as paired panels, with the left panels summarizing the 
concentration-response relationship, and the right panel presenting the contribution of 
vascular nitric oxide production in terms of impacting phenylephrine-induced constriction 
where the change in the upper bound of this relationship is shown following treatment of 
the arteriole with L-NAME.  Data are presented for animals at 7 weeks (Panels A/B), 10 
weeks (Panels C/D), 13 weeks (Panels E/F) and 17 weeks (Panels G/H) of age.  * p<0.05 
vs. LZR; † p<0.05 vs. OZR.    
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 Figure 6.  The relation between plasma total cholesterol level (Panel A), or a proxy variable 
for NO bioavailability (upper bound of the acetylcholine dose-response relationship; Panel 
B), and microvessel density from the different animals in the present study.  Each animal 
used in the study, across the experimental groups is presented in this figure.  The inset text 
presents the linear regression equation that best fits these data and the degree to which 
that equation explains the variability in the data.   
 
Figure 7.  Summary plot for the results of the discriminant analyses in the present study.   
These results provide the functions 1 and 2 (presented in Table 3) which contribute the 
majority (>90%) of the differences between the experimental groups at each age.  
Specifically, RANTES, IL-10, MCP-1 and TNF-α play the greatest role in terms of 
establishing differences between LZR (light blue), OZR (green), and OZR under the four 
treatment conditions of the present study; gemfibrozil (grey), probucol (purple), simvastatin 
(orange) and atorvastatin (red).  The centroids for each group are presented in the dark 
blue squares. 
 
Figure 8.   Relationships between the four most significant markers of inflammation 
(identified using discriminant analyses; please see text for details), vascular NO 
bioavailability, and gastrocnemius muscle microvessel density for animals in the present 
study.  Data are presented for RANTES (Panel A), IL-10 (Panel B), MCP-1 (Panel C), and 
TNF-α (Panel D), and the same color coding is used as in Figure 4; LZR (light blue), OZR 
(green), and OZR+GEM (grey), OZR+PRO (purple), OZR+SIM (orange) and OZR+ATOR 
(red).   
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 Figure 3.   
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 Figure 4.  
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 Figure 5.    
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ABSTRACT 
The metabolic syndrome represents an integrated metabolic and cardiovascular 
disorder reflecting the development of multiple risk factors for a poor cardiovascular 
outcome, including obesity, insulin resistance, dyslipidemia, hypertension and the 
genesis of pro-inflammatory and pro-oxidant environments.  The obese Zucker rat 
(OZR) represents an excellent model of metabolic syndrome, and develops this 
condition due to chronic hyperphagia.  While impairments to vascular reactivity with 
metabolic syndrome have been well established and are partly a function of reduced 
nitric oxide bioavailability and altered arachidonic acid metabolism, we have made the 
novel and consistent observation that reductions to skeletal muscle microvascular 
density (rarefaction) also develop in parallel with reactivity alterations, and that this 
plays a key contributing role in contributing to disparities between matching metabolic 
demand to perfusion.  While our previous publications have demonstrated that the full 
extent of rarefaction is well predicted by a chronic loss of nitric oxide bioavailability, our 
most recent data strongly suggest that an early pulse of rarefaction develops very 
rapidly in the OZR model of metabolic syndrome which significantly precedes any 
demonstrable loss in NO bioavailability.  Our advanced statistical analyses have 
suggested that the strongest associated parameter with the early pulse of microvascular 
rarefaction is a shift in vascular arachidonic acid metabolism from prostacyclin (PGI2) to 
thromboxane A2 (TxA2).  Presented within this manuscript are data supporting a role for 
TxA2 elevations in early rarefaction and underlying role for elevations in oxidant stress 
and TNFα levels in the elevations in TxA2 production. 
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INTRODUCTION 
With the development and maintenance of an obese state comes the 
establishment of pro-oxidant (22; 28; 32; 40), pro-thrombotic (1; 31), and pro-
inflammatory (8; 24; 26; 35) conditions along with concurrent development of insulin 
resistance (25; 34; 43), dyslipidemia (29), and hypertension (2).  This constellation of an 
initiating pathology of obesity along with its associated co-morbidities is clinically 
classified as the “metabolic syndrome” (38).  It is estimated that as many as 50 million 
Americans (38) currently fit the requisite criteria for diagnosis of metabolic syndrome 
with those numbers steadily increasing both nationally (7) and globally (23).  While each 
individual pathology associated with metabolic syndrome is significant, their greatest 
impact on public health is that they dramatically increase the risk for developing 
peripheral vascular disease, resulting in an imbalance between skeletal muscle demand 
and adequate perfusion (12; 13; 18; 41; 42).  This imbalance in demand:perfusion 
matching leads to ischemia (15), compromised tissue function (15), diminished tissue 
viability(37) and quality of life issues (37).   
The obese Zucker rat (OZR) serves as an established model of metabolic 
syndrome, owing to a dysfunctional leptin receptor gene which results in a chronic state 
of hyperphagia.  These animals become rapidly obese and, in turn, develop insulin 
resistance, dyslipidemia and moderate hypertension along with the pro-thrombotic, pro-
inflammatory and pro-oxidant environment characteristic of their human metabolic 
syndrome counterparts.  Previous studies by multiple investigative groups have 
demonstrated negative vascular outcomes in OZRs with the development of metabolic 
syndrome, including alterations to vascular wall mechanics, impairments to multiple 
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indexes of dilator reactivity, alterations to signaling mechanisms underlying constrictor 
reactivity, and a rarefaction of microvascular networks within multiple tissues(6; 15; 18; 
19; 40; 42). The culmination of these alterations to microvascular structure and function 
within OZRs can result in profound impairments to the perfusion of tissue under an 
array of physiological and pathological conditions. 
In recent years, studies have demonstrated that alterations to arachidonic acid 
metabolism (AA) through the cyclooxygenase (COX) pathway may contribute to the 
demand:perfusion disparities seen in OZRs.  AA is stored in the cell membrane of most 
resting cells, esterified to glycerol groups of phospholipids (9).  It is released from this 
“stored” esterified state when activated phospholipases (A, C or D) catalyze hydrolysis 
of the phospholipid thereby allowing for AA desequestration (9).  Upon release, this free 
arachidonate can: be reincorporated into phospholipids, diffuse away from the cell, or 
diffuse into the cell at which time it is subject to metabolism (30).  The metabolism of 
arachidonic acid is characterized by three major pathways: Cyclooxygenase, 
Lipoxygenase and Cytochrome P450. Alterations to relative metabolism through each of 
these pathways has been demonstrated to occur in a number of disease states (3-5; 
33).  Recent studies have demonstrated a shift in the balance of TxA2 and PGI2 
produced downstream from COX with a predomination of TxA2 production resulting in 
attenuated dilator responses as the constrictor prostanoid TxA2 blunts the response of 
the typically predominant COX dilator prostanoid, PGI2 (20; 36; 36; 40).   
In addition to the above mentioned vasomotor dysfunction found in metabolic 
syndrome, there are significant vascular network remodeling components in the skeletal 
muscles of metabolic syndrome individuals and OZRs.  There is a well documented and 
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progressive loss of tissue capillarity in metabolic syndrome subjects termed rarefaction 
(21; 27; 39).  This rarefaction process while well documented, is only poorly understood.  
Recent work from this lab has attributed much of the rarefactive process to diminished 
NO bioavailability as therapeutics which spared NO were also able to maintain tissue 
microvessel density (10; 11; 16).  This study re-examines those earlier findings which 
focused on tissue microvessel density during a single timepoint and attempts to 
establish the progression of rarefaction as it parallels development of the metabolic 
syndrome.  Rather than wait for the classically employed 17-week age range wherein 
OZRs are showing all major symptoms of the metabolic syndrome, this study begins at 
7 weeks of age where metabolic syndrome symptoms are intermediate at best.  The 
novel observation of this work is that our understanding of rarefaction is not inaccurate 
though it is incomplete.  There does, indeed, appear to be a NO mediated phase of 
rarefaction but only subsequent to an early and mechanistically distinct rarefactive 
process mediated by the obesity associated shift in prostanoid production through the 
COX pathway. 
The purpose of the present study was to identify key contributors to the process 
of obesity related skeletal muscle microvascular rarefaction in an established animal 
model of the metabolic syndrome.  Based on the existing data set, the hypothesis to be 
tested was that metabolic syndrome mediated rarefaction is a linear process regulated 
by a single major mechanism. This somewhat implausible hypothese was rapidly 
disproven as studies demonstrated that the process of rarefaction is far more complex.  
Rarefaction in metabolic syndrome is neither linear nor mediated by a single 
mechanism.  The system is regulated by multiple, temporally and mechanistically 
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distinct mechanisms with an early rarefactive pulse mediated by shifts in prostanoid 
production and a later pulse mediated by diminished NO bioavailability. 
MATERIALS AND METHODS: 
Animals:  Male LZRs and OZRs (6-20 wks old, as indicated; 17 weeks old if not 
otherwise indicated) were used for all experiments. Rats were fed standard chow and 
tap water ad libitum.  After an overnight fast, rats were anesthetized with injections of 
pentobarbital sodium (50 mg/kg ip) and received tracheal intubation to facilitate 
maintenance of a patent airway. In all rats, a carotid artery and an external jugular vein 
were cannulated for the determination of arterial pressure and for the intravenous 
infusion of supplemental anesthetic, if necessary. Blood was drawn from the jugular 
vein to be used for the biochemical determination of plasma glucose (Freestyle, Abbott 
Diabetes Care, Alameda, CA), insulin (Millipore, St. Charles, MO), and measurements 
for TNFα (Millipore, St. Charles MO) as well as a plasma lipid profile (Stanbio, Boerne, 
TX) and nitrotyrosine (Oxis, Foster City, CA) from each animal.  Chronic TNFα inhibition 
was accomplished in a subset of these animals through daily i.p. injection of the TNFα 
inhibitor pentoxifylline [30mg/kg/day].  In additional subsets of animals oxidant 
scavenging was achieved through the use of the membrane permeable superoxide 
dismutase mimetic 1-Oxyl-2,2,6,6-tetramethyl-4-hydroxypiperidine (TEMPOL) [10
-3
M in 
drinking water].  In all animals, water consumption was monitored daily to assure that 
dosing was within expected parameters. 
Histological Determination of Microvessel Density: With the rat under anesthesia, 
the right gastrocnemius muscle was removed, rinsed in PSS, and lightly fixed in 1% 
formalin. Muscles were then embedded in paraffin and cut into 5-μm cross sections, and 
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stained for Griffonia simplicifolia I lectin (Sigma). From each gastrocnemius muscle, six 
randomly selected individual cross sections were used for analysis, with six randomly 
selected regions within an individual cross section chosen for study. Each region of 
study had an area of ~1.47 X 10
5
 μm
2
. After staining, sections were rinsed three times 
in PSS and mounted on microscope slides with a water-soluble mounting medium (SP, 
ACCU-MOUNT 280, Baxter). With the use of epifluorescence microscopy, localization 
of lectin stained microvessels was performed with a Nikon Eclipse 80i upright 
microscope with a X20 objective lens (Plan Fluo phase, numerical aperture 0.5). 
Excitation was provided by a 75-W xenon arc lamp through a Lambda 10-2 optical filter 
changer (Sutter Instruments; Novato, CA) controlling a 595-nm excitation filter and 615-
nm emission filter. The microscope is coupled to a cooled charge-coupled device 
camera (Photometrics CoolSNAP ES). 
Determination of Vascular TxA
2
 Production: Vascular production of 11-dehydro-
thromboxane B
2
 [the stable plasma breakdown product of TxA
2
] was assessed using 
pooled conduit arteries (femoral, saphenous, and iliac arteries) from LZRs and OZRs 
(treated & control).  Pooled vessels from each animal were incubated in microcentrifuge 
tubes in 1 ml PSS for 30 min under control conditions (21% O
2
) at room temperature 
and stimulated with an addition of exogenous arachidonic acid (10
-5
 M). After the 30-min 
period, this PSS was transferred to a fresh tube, frozen in liquid N
2
, and stored at -80°C. 
Metabolite release by the vessels was determined using commercially available EIA kits 
for 11-dehydro-TxB
2
 (Cayman Chemicals). 
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Determination of Vascular Nitric Oxide Bioavailability: From each animal, the 
abdominal aorta was removed and vascular NO production was assessed using 
amperometric sensors (World Precision Instruments). Briefly, aortae were isolated, 
sectioned longitudinally, pinned in a silastic coated dish, and superfused with warmed 
(37◦C) PSS equilibrated with 95% O2 and 5% CO2. The NO sensor (ISO-NOPF 100) 
was placed in close apposition to the endothelial surface and a baseline level of current 
was obtained. Subsequently, increasing concentrations of methacholine (10
−10
–10
−6
 M) 
were added to the bath and the changes in current were determined. To verify that the 
recorded data represented endothelium-dependent NO release, responses were 
reevaluated following acute treatment of the aortae with L-NAME (10
−4 
M). 
Statistical Analyses: As this work is preliminary, each group contains 3-4 animals.  As 
such, the study is too insufficiently powered to provide statistical analyses at this time.  
Ongoing work will, ultimately, provide greater power allowing for the employment of 
appropriate statistical methods.  The notable exception to this occurs in Table 1 which 
draws on a more robust data set allowing for animal groups of 8. 
RESULTS 
 Baseline characteristics of lean and obese Zucker rats are presented in Table 1.  
The OZR shows significantly increased mass as early as 6 weeks of age, when 
compared to age matched lean counterparts, with the disparity in lean vs. obese mass 
only becoming more pronounced with time.  Additionally, by 6 weeks of age, obese 
Zucker rats clearly demonstrate hyperinsulemia as well as hypertriglyceridemia.  By 12 
weeks of age, the obese Zucker rat additionally manifests hyperglycemia with 
demonstrable hypercholesterolemia finally manifesting at 17 weeks of age.  
139
 Owing to the fact that the obese Zucker rat demonstrates all measured metrics of 
metabolic syndrome employed in this study by 17 weeks of age, initial measures of the 
effects of metabolic syndrome on tissue capillarity were performed within this age 
window.  Results of these analyses are demonstrated in Figure 1A which clearly 
demonstrates a nearly 30% loss of microvessel density (rarefaction) when comparing 
the gastrocnemius muscle microvessel density in 17 week old lean and obese Zucker 
rats.  Acknowledging that the metabolic syndrome is a process that develops over time 
in the Zucker rat and supported by the evidence shown in Table 1, further analyses of 
the temporal effects of metabolic syndrome on skeletal muscle microvessel density 
were performed from 7 to 20 weeks of age in approximately 3 week iterations.  The 
results of these analyses, summarized in Figure 1B, demonstrate that at 7 weeks of 
age, obese Zucker rats maintain normal tissue capillarity despite the elevated mass, 
plasma insulin and triglyceride levels demonstrated in Table 1.  However, given time, 
these rats undergo a biphasic rarefactive process wherein there is an early period of 
rarefaction from 7 to 10 weeks of age constituting an approximate 15% loss of 
microvessel density in the gastrocnemius muscle.  This early rarefaction is followed by a 
plateau from 10-13 weeks of age wherein there is no apparent loss of microvessel 
density.  Subsequent to the rarefactive plateau is a late phase of rarefaction 
accountable for the remaining 15% loss of microvessel density.  Analyses to 20 weeks 
of age and beyond (data not shown) demonstrate that this capillarity remains relatively 
constant through the remainder of the animal’s life. 
 Previous studies from this laboratory have demonstrated an inverse relationship 
between vascular NO bioavailability and skeletal muscle microvessel density in the 
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Zucker rat (17; 18).  Since these studies were performed in the 17 week age with no 
attention to the temporal contribution, and owing to the data in Figure 1B demonstrating 
a biphasic phenomenon, vascular NO bioavailability was assayed across the 7 to 20 
week age time-course of the study.  Figure 2A clearly demonstrates significant 
impairment to vascular NO bioavailability beginning at 13 weeks of age with more 
pronounced impairment at later time-points.  This coincides well with late rarefaction, 
while removing NO bioavailability as a likely causative agent in early rarefaction.  Based 
on previous work in this lab which demonstrated impairments in COX mediated 
prostanoid balances in the obese Zucker rat, favoring a production of TxA2 over 
prostacyclin (19), stimulated vascular production of TxA2 was measured in all time 
points.  Figure 2B, which summarizes the results of these analyses, demonstrates that 
vascular production of 11-dehydro-thromboxane-B2, the stable breakdown product of 
TxA2 is drastically elevated across the period of early rarefaction and remains so 
through 20 weeks of age. 
 Determination of a mechanistic linkage between elevations in TxA2 production 
and early rarefaction was accomplished by competitively antagonizing the TxA2 
receptor, TP, with the compound SQ-29548.  Figure 3A shows the results of this study 
wherein early rarefaction was abolished in obese Zucker rats via treatment with SQ-
29548 with no apparent non-specific effects of the compound on lean control animals.  
Figure 3B shows the results of an early withdrawal study where animals received SQ-
29548 from 6 to 13 weeks of age, however, at 13 weeks of age treatment was 
discontinued.  The results of this portion of the study demonstrate that rarefaction 
begins anew immediately following discontinuation of TP receptor antagonism. 
141
 Figure 4 summarizes the data related to determining the mechanistic 
underpinnings of obesity associated elevations in TxA2.  Figures 4A and 4B 
demonstrate drastic elevations in systemic oxidant stress and plasma TNFα 
concentrations, respectively, with increasing duration of the metabolic syndrome.  In 
both the case of oxidant stress and inflammation, elevations occur early and levels of 
both nitrotyrosine and TNFα remain elevated through the time-course in untreated 
obese Zucker rats.  Elevations in oxidant stress were diminished via treatment with the 
membrane permeable superoxide dismutase mimetic TEMPOL while production of 
TNFα was inhibited through the use of pentoxifylline.  The effects of these inhibitions on 
stimulated vascular TxA2 production is summarized in Figure 4 panels C and D.  
Chronic diminishment of superoxide levels resulted in an intermediate production of 
TxA2 across the time-course.  This same effect was seen in the case of TNFα synthesis 
inhibition where chronic pentoxifylline treatment was able to maintain intermediate 
levels of TxA2.  The phenotypic consequences of chronic inhibition of oxidant stress 
mechanisms or TNFα mediated inflammatory mechanisms are summarized in Figure 4 
panels E and F. Panel E demonstrates that chronic inhibition of superoxide mediated 
effects is sufficient to blunt but not abolish the rarefactive process demonstrated with 
continued duration of metabolic syndrome in obese Zucker rats.  In contrast, Panel F 
demonstrates that inhibition of the inflammatory mediator TNFα with pentoxifylline is 
sufficient to abolish rarefaction in obese Zucker rats through 17 weeks of age. 
DISCUSSION 
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 With the development of metabolic syndrome comes the inevitable loss of ability 
to match demand and perfusion in peripheral tissues (12; 14).  Numerous investigations 
have demonstrated that alterations to vasomotor function significantly contribute to the 
inability to properly regulate perfusion into these tissues.  However, even when the 
influences of vasomotor alterations are systematically removed, perfusion levels still 
remain impaired with increasing metabolic demand (10) .  This impairment is attributed 
to a bulk loss of microvessels/capillaries in these peripheral tissues, a process termed 
rarefaction.   
 Despite the phenomenon of rarefaction being clinically and experimentally well 
established, the mechanistic underpinnings of the process are poorly understood.  
Previous work has demonstrated that capillary losses parallel loss in nitric oxide 
bioavailability and with experimental evidence to support the rationale that the loss in 
tissue capillarity is a direct result of diminished NO bioavailability (11; 18).  These 
previous studies have provided tremendous insight into the mechanisms leading to 
rarefaction and resulting in perfusion demand disparities but have suffered from the lack 
of an adequate temporal component. 
 As Table 1 in this study demonstrates, the development of metabolic syndrome 
occurs along a temporal continuum with some aspects preceding others by necessity.  
For instance, obese Zucker rats manifest demonstrable hyperinsulemia as early as 6 
weeks of age.  This hyperinsulemia must, by necessity precede any notion of the animal 
being a model of type II diabetes as glycemic control remains unimpaired until 12 weeks 
of age.  By logical extension, the fact that the animal suffers from fewer comorbities 
than those found at later time-points in the disease could have significant impact on the 
143
effects of the metabolic syndrome on skeletal muscle microvessel density.  Though this 
distinction seems trivial in an animal that is able to fully manifest a metabolic syndrome 
phenotype by 17 weeks of age, the implications in humans are far more significant as 
development of metabolic syndrome is a much more gradual process typically taking 
years or even decades to fully manifest. 
 The most obvious and significant finding of this study is found in Figure 1 panel B 
which highlights the biphasic nature of obesity related microvascular rarefaction.  Prior 
to the onset of a type II diabetic phenotype, in the 7-10 week age window, a rarefactive 
pulse constituting ~50% of the total microvessel loss occurs.  It is not until 13 weeks of 
age that a second rarefactive pulse occurs resulting in all remaining rarefaction.  As this 
window is subsequent to the development of diabetes at approximately 12 weeks of 
age, the second rarefaction highlights the notion that as the pathologies evolve so do 
the consequences of those pathologies.  An admitted limitation of this study is the lack 
of attempt to correct the diabetes in these animals to determine its contributions to later 
rarefaction.  What does become evident even in these early figures, however, is that 
microvascular rarefaction in the metabolic syndrome is not the simple linear process 
that it is often portrayed to be. 
 The logical extension of a biphasic process is that each phase may be mediated 
through distinct processes.  Data supporting this hypothesis are presented in Figure 2 
which shows that the loss of NO bioavailability occurs in obese Zucker rats subsequent 
to the early rarefactive period precluding the possibility of NO reductions being a 
causative agent in the early microvessel loss.  Building on data from previous studies 
which demonstrated a shift in vascular prostanoid production with obesity, Figure 2 
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panel B presents the possibility of elevations in TxA2 as a causative factor in early 
rarefaction.  This correlative data are then further extended to demonstrate causality as 
antagonism of the TxA2 signaling pathway results in total ablation of early rarefaction 
(Figure 3).  Perhaps more interesting was the discovery that when antagonism of the 
TxA2 pathway was discontinued, rarefaction was renewed but blunted as indicated by 
the diminished slope of rarefaction in 13-17 week window.  While further studies are 
required to determine what mediates this post-therapeutic rarefaction, the 13-17 week 
blunting would strongly indicate that early TxA2 elevations are either necessary for later 
rarefaction and have some sort of causative relationship to NO bioavailability reductions 
or the TxA2 elevations somehow exacerbate the effects of NO bioavailability reductions 
enhancing the consequence of those reductions with regards to rarefaction.  Whatever 
the case may be, the evidence provided by these data indicates that while the two 
phases of rarefaction are mechanistically distinct, they may also be interconnected. 
 The final figures of this study attempt to demonstrate the cause of these 
elevations in TxA2 production with obesity.  A significant consequence early in the 
metabolic syndrome is the development of a pro-inflammatory and pro-oxidant 
environment. As increased oxidative stress and inflammation is able to activate 
numerous signaling pathways, they serve as logical targets of investigation for changes 
in the production of essentially any vascular metabolite.  Additionally, work from our lab 
and others has implicated elevations in superoxide and TNFa, specifically, in alterations 
to TxA2 production.  Figure 4 clearly demonstrates that both superoxide and TNFa 
elevations contribute to elevations in vascular TxA2 levels with the phenotypic 
consequence of enhanced rarefaction.   
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 Taken together, these data demonstrate that metabolic syndrome related 
microvascular rarefaction is a biphasic process in which each phase is both temporally 
and mechanistically distinct.  Early rarefaction is mediated by elevations in vascular 
TxA2 levels whereas late rarefaction is mediated by diminished vascular NO 
bioavailability.  Preliminary evidence would indicate that the later phase of rarefaction is 
at least partially enhanced, if not totally dependent, on early rarefactive processes.  
Additionally, these early TxA2 mediated rarefactive processes are the result of 
elevations in systemic oxidant stress and systemic inflammation.  Taken together these 
data highlight the TxA2 pathway as a target for potential future investigations into 
therapeutic treatments for metabolic syndrome related skeletal muscle microvascular 
rarefaction.  Additionally this study supports the idea of prophylactic treatment of 
metabolic syndrome subjects with anti-inflammatory and anti-oxidant drugs as this study 
provides another example of an instance where pathophysiologic elevations in either of 
those two systems is deleterious to cardiovascular outcome. 
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Table 1 
 
6 Weeks 9 Weeks 12 Weeks 15-17 Weeks 20 Weeks
Mass (g) 142+8 202+10 270+11 364+12 385+13
Mean Arterial Pressure (mmHg) 89+4 105+4 101+5 105+4 109+6
[Glucose]blood (mg/dl) 106+14 111+10 106+14 121+13 125+14
[Insulin]plasma (ng/ml) 1.4+0.4 1.2+1.1 1.0+0.5 1.5+0.6 1.4+1.0
[Triglycerides]plasma (mg/dl) 76+9 81+13 81+12 88+11 91+15
[Cholesterol]plasma (mg/dl) 67+8 69+8 71+11 74+8 84+11
6 Weeks 9 Weeks 12 Weeks 15-17 Weeks 20 Weeks
Mass (g) 184+10* 288+15* 401+14* 602+15* 680+16*
Mean Arterial Pressure (mmHg) 88+5 110+5 118+4* 128+6* 129+5*
[Glucose]blood (mg/dl) 102+12 130+18 168+16* 184+18* 188+14*
[Insulin]plasma (ng/ml) 2.5+0.4* 6.9+1.1* 8.6+2.0* 9.4+1.4* 10.4+1.9*
[Triglycerides]plasma (mg/dl) 122+16* 168+14* 167+15* 309+15* 384+16*
[Cholesterol]plasma (mg/dl) 74+10 85+10 107+13 128+12* 136+12*
Lean Zucker Rats
Obese Zucker Rats
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FIGURE LEGENDS 
Figure 1. Microvessel density in the gastrocnemius muscle of 17 week old (Panel A) or 
temporally progressing (Panel B) lean and obese Zucker rats.  Data are presented as 
mean + SEM.  
Figure 2. Stimulated vascular NO bioavailability (Panel A) or stimulated vascular 
thromboxane B2 production (Panel B) measured with amperometric sensors or via 
ELISA, respectively, as assayed in pooled conduit arteries.  Data are presented as 
mean + SEM. 
Figure 3. Panel A shows microvessel density in the gastrocnemius muscles of lean and 
obese Zucker rats receiving SQ-29548 therapies or left as untreated controls from 7-13 
weeks of age.  Panel B demonstrates gastrocnemius muscle microvessel density in 
animals receiving the same treatment as in Panel A, with discontinuation of therapy at 
13 weeks but measurement of density continuing to 20 weeks. 
Figure 4.  Figure 4 displays the elevations in oxidant stress as indicated by plasma 
nitrotyrosine levels (Panel A) along with effects of anti-ROS therapies on stimulated 
thromboxane production (Panel C) and ultimate consequence on microvessel density 
(Panel E).  Elevations in TNFα levels are highlighted in Panel B with the effects of anti-
TNFα therapies on TxB2 (Panel D) levels and microvessel density (Panel F) shown in 
subsequent panels.  
156
Figure 1 
M
ic
ro
ve
ss
el
 D
en
si
ty
 (#
/m
m
2 )
600
700
800
900
1000
LZR
OZR
A
 
 
Animal Age (weeks)
7 10 13 17 20
M
ic
ro
ve
ss
el
 D
en
si
ty
 (#
/m
m
2 )
500
600
700
800
900
1000
LZR
OZR
B
 
  
157
Figure 2 
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Figure 3 
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Figure 4 
Animal Age (weeks)
7 10 13 17 20
P
la
sm
a 
N
itr
ot
yr
os
in
e 
C
on
ce
nt
ra
tio
n 
(n
g/
m
l)
0
20
40
60
LZR
OZRA
Animal Age (weeks)
7 10 13 17 20
P
la
sm
a 
TN
F-
α C
on
ce
nt
ra
tio
n 
(p
g/
m
l)
0
2
4
6
8 LZR
OZRB
 
 
Animal Age (weeks)
7 10 13 17 20
11
-d
eh
yd
ro
-T
xB
2
0
20
40
60
80
100
120
140
160
LZR
OZR
OZR+TEMPOLC
Animal Age (weeks)
7 10 13 17
Va
sc
ul
ar
 1
1-
de
hy
dr
o-
Tx
B
2 
Pr
od
uc
tio
n 
(p
g/
m
g)
20
40
60
80
100
120
140
160
LZR-C
LZR-P 
OZR-C
OZR-P 
**‡
‡
‡
‡
D
 
Animal Age (weeks)
7 10 13 17 20
M
ic
ro
ve
ss
el
 D
en
si
ty
 (#
/m
m
2 )
550
600
650
700
750
800
850
900
950
LZR
OZR
OZR+TEMPOL
E
Animal Age (weeks)
7 10 13 17
M
ic
ro
ve
ss
el
 D
en
si
ty
 (#
/m
m
2 )
0
200
400
600
800
1000
LZR-C
LZR-P
OZR-C
OZR-P‡ ‡
‡
∗
F
 
 
160
  
 
Chapter 6 
 
 
 
 
Discussion 
  
161
 The purpose of the studies presented within this work was to demonstrate the 
global systemic consequences of alterations to AA metabolism on both the vasomotor 
function and vascular network structure within the skeletal muscle of a well-established 
rodent model of the metabolic syndrome.  We first sought to demonstrate that the 
alterations to AA metabolism, specifically through the cyclooxygenase pathway, do 
occur and that these alterations have significant consequences on the regulation of 
skeletal muscle vascular tone.  This was accomplished by employing a clean stimulus 
for the production of prostacyclin, a COX pathway end-product, in both obese Zucker 
rats and their age matched lean counterparts.  This study, which is presented in chapter 
2 of this document, was able to demonstrate a blunted hypoxic dilation which was 
mediated exclusively by modest reductions in prostacyclin production and impressive 
increases in the production of the vasoconstrictor thromboxane A2 within the vascular 
endothelium.  Further evidence within the same study was able to identify elevations in 
vascular superoxide levels as a causative factor in the shift from a predominant 
prostacyclin production induced vasodilation to a blunted vasodilation stemming from 
pathophysiologic overproduction of thromboxane A2.  This phenomenon could be 
blunted through treatment with a pegylated form of superoxide dismutase which 
returned production of thromboxane A2 to a more physiologic level while having no 
effects on prostacyclin production.  Interestingly, while the effects of enhanced 
superoxide levels on prostacyclin production were non-existent, PEG-SOD treatment 
was sufficient to largely restore a documented diminished sensitivity of the vessel to 
prostacyclin to normal levels.  Taken together, these data provided the foundational 
work for investigations into metabolic syndrome related alterations in COX mediated AA 
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metabolism as well as the underlying role of superoxide in this imbalance between 
prostacyclin and thromboxane. 
 Building on this previous work, investigations were performed in murine models 
of dyslipidemia, the LDLR knockout mouse and the ApoE knockout mouse.  These 
animals manifest only a single comorbidity of the metabolic syndrome but were 
interesting as work presented in “Differential Impact of Familial Hypercholesterolemia 
and Combined Hyperlipidemia on Vascular Wall and Network Remodeling in Mice” by 
Stapleton et al. provided correlative data between alterations in vascular wall 
mechanical responses and elevations in thromboxane A2 in these particular animal 
models.  This provided us with the idea that perhaps the dyslipidemia demonstrated in 
metabolic syndrome, in some way led to the elevations in TxA2 and in turn the 
vasomotor consequences that had been demonstrated in fully vested animal models of 
the metabolic syndrome, as detailed in Chapter 2.  This provided the impetus for the 
investigations detailed in Chapter 3, wherein similar alterations to AA metabolism as 
those found in the Zucker rat are demonstrated with a recapitulation of the significance 
of enhanced ROS levels as a mediator of these alterations.  Further, this manuscript 
demonstrated the relative insignificance of lipoxygenase and cytochrome p450 
pathways in the observed vasculopathies as treatments with inhibitors of each pathway 
showed no effects on system responses.   
 Based on this compelling evidence in dyslipidemic mice, and in accordance with 
documented vasoprotective effects of chronic statin therapies in humans and animal 
models, we next set out to determine whether chronic reductions in circulating 
cholesterol levels would be able to restore normal metabolism of AA via COX and, in 
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turn, confer a protective effect on the vasculature with regards to vasomotor function.  
This body of work is summarized in Chapter 4 and clearly demonstrates the ability of 
statin therapies to protect against metabolic syndrome related vasculopathies 
regardless of whether those vasculopathies were vasomotor, wall mechanical or 
network structural in nature.  The most significant result of this study was the 
demonstration that this protection occurs independent of any effects of the therapeutic 
regimen on cholesterol levels.  This was conveyed by treating animals with either statins 
(HMG-CoA reductase inhibitors) thereby diminishing the biosynthesis of cholesterol or 
fibrates whose effects increase the fractional clearance of LDL while also diminishing 
absorption of LDL by the LDL-receptor.  Table 1 within chapter 4 illustrates the ability of 
all therapeutics to significantly lower plasma cholesterol levels in treated animals.  
However, both the fibrates gemfibrozil and probucol failed to significantly protect against 
any of the previously mentioned categories of vasculopathy as evidenced by negligible 
impact of either of these therapies in any of the subsequent figures which assayed 
acetylcholine mediated dilator responses, gastrocnemius muscle microvessel density 
and arteriolar incremental distensibility.  The key finding of this study was that only 
those therapeutics that were capable of protecting against a loss of vascular NO 
bioavailability were capable of conferring vasoprotective effects and these effects in 
turn, appeared to be mediated by the drugs ability to attenuate chronic inflammatory 
responses.   
 We next undertook a more thorough examination of the process of microvascular 
rarefaction in the metabolic syndrome.  The details of Chapter 4, along with previous 
work, strongly indicated that microvascular rarefaction is mediated by the loss of 
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vascular NO bioavailability and that those therapies capable of protecting against the 
loss of NO bioavailability had the predictable outcome of protecting against skeletal 
muscle microvascular rarefaction.  It is in the experiments detailed in Chapter 5, where 
we first set out to determine the time-course of microvascular rarefaction.  The initial, 
unexpected result of this study is shown in Figure 1B of Chapter 5 which clearly 
demonstrates a biphasic rarefactive process ongoing in these animals.  The initial 
hypothesis upon which this work was operating was that, microvascular rarefaction is a 
linear process beginning in pre-metabolic syndrome animals with normal microvessel 
density and progressing in a linear fashion through the time-course of the disease until 
such time as minimum viable tissue capillarity is achieved.  The identification of a 
biphasic nature to the rarefaction immediately precluded this hypothesis from 
succeeding to be proven and additionally provided cause to re-evaluate the hypothesis 
that microvascular rarefaction is mediated by loss of vascular NO bioavailability.  It is 
plausible that if a process demonstrates two temporally distinct phases, those phases 
may well be mechanistically independent as well. 
 Investigations into the mechanistic underpinnings of early rarefaction, 
immediately ruled out reductions in NO bioavailability as a mediator of microvessel loss, 
as stimulated vascular production of NO is indistinguishable during the time period of 
early rarefaction when comparing age matched lean and obese Zucker rats.  However, 
late phase microvascular rarefaction demonstrated a strong and inverse relationship to 
vascular NO bioavailability which, when taken with the previous data, still indicates that 
the later phase of rarefaction is mediated by NO loss.  Based on the previously 
established information of Chapters 2-4, there was sufficient evidence to indicate the 
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possibility that altered inflammatory status and elevations in systemic oxidant stress 
could be impacting COX mediated metabolism and that this alteration could have 
effects on rarefaction.  The data outlined in Chapter 5 demonstrate that there are 
alterations to AA metabolism that occur early in the development of the OZR, resulting 
in drastic elevations in TxA2 during the period of early microvascular rarefaction.  
Further, when the effects of these elevations are blocked by antagonism of the TxA2 
cognate receptor TP by treatment with the competitive antagonist, SQ-29548, there is a 
complete abolition of early microvascular rarefaction.  This effect on early rarefaction 
can be blunted through alternative pathways, as demonstrated by treatment with the 
anti-TNFa synthesis compound pentoxifylline or treatment with the oxidant scavenger 
TEMPOL.  Both therapeutics were capable of drastically diminishing elevations in TxA2 
and, by extension, early rarefaction.  Finally, this study demonstrated the effects of early 
withdrawl from the compound wherein animals were treated through the entire phase of 
early rarefaction with the TP receptor antagonist SQ-29548 but then removed from 
treatment in a fashion temporally consistent with the end of early rarefaction.  What was 
demonstrated was that although rarefaction began anew, this delayed rarefactive 
process was diminished in intensity from the anticipated 15% rarefaction that generally 
occurs with late phase rarefaction to approximately a 6% loss of total microvessel 
density.   
 What requires the greatest scrutiny for future investigation is what mediated that 
pulse of late rarefaction during the early withdrawl study.  Whether this late phase 
rarefaction was still a NO mediated process or whether it was just a delayed TxA2 
mediated rarefaction has yet to be determined.  Additionally, regardless of the 
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mechanism by which the delayed rarefaction occurred, there was a significant blunting 
of microvessel loss.  This speaks to interplay between early and late rarefaction.  It’s 
possible that the early loss of microvessels through the thromboxane mediated process 
in some way primes the system for the later loss.  Alternatively, it’s additionally possible 
that TxA2 elevations in some way sensitize the system to a greater need of NO for 
maintenance of microvessel density, essentially altering the gain of the system with 
regards to NO sensitivity and microvessel sparing.  Regardless of the mechanism, 
interplay is apparent as there are obvious effects of blocking early rarefaction on 
subsequent later microvessel loss. 
 The supplementary document mentioned in the introduction of this dissertation, 
“Aspirin Resistance with Genetic Dyslipidemia: Contribution of Vascular Thromboxane 
Generation” by Frisbee et al. serves as a cautionary to target selection.  Aspirin therapy 
is one of the most commonly prescribed prophylaxes in the world today (5).  Numerous 
studies have demonstrated the ability to increase the likelihood of survivability of major 
cardiac events in those individuals on a chronic, low-dose, aspirin regimen (2-6).  
Aspirin serves in this capacity through its ability as a COX-2 inhibitor, decreasing TxA2 
production by platelets and diminishing platelet aggregation with the result of reducing 
chance of thrombus formation (2).  Based on this work, COX-2 selective drugs have 
been developed for the purpose of prophylaxis primarily in individuals with some form of 
chronic inflammatory disease.  What has received significant media attention is the 
voluntary recall of the selective COX-2 inhibitor Vioxx which was found to significantly 
increase the probability of negative outcomes from a major cardiovascular event.  To 
many, this finding was unsurprising since you lose the contributions of prostacyclin, 
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prostaglandins and thromboxane in the regulation of vascular tone through this highly 
upstream inhibition.  Where Appendix II serves as a cautionary is in its demonstration of 
dyslipidemic mice to lose sensitivity to chronic aspirin therapies.  Essentially, after any 
significant period of time with profound dyslipidemia, in mice, the prophylaxis with 
Aspirin loses any therapeutic value.  While studies have to be performed in a fully 
vested model of metabolic syndrome, logical extension is that since these animals 
demonstrate similarly profound dyslipidemia, a similar resistant phenotype will emerge.  
Additionally, since the vasomotor and network consequences of COX metabolites 
seems to stem from an imbalance in their production as opposed to a uniform 
overproduction of all COX metabolites, more selective downstream targets will logically 
have greater therapeutic potential. 
 Conjecture based on the data presented within this work leads to the following 
conclusions.  There are significant consequences to the peripheral vasculature resulting 
from an imbalance of COX metabolites with moderately diminished prostacyclin 
production and sensitivity coupled with drastically elevated TxA2 production resulting in 
enhanced vascular tone, blunted dilator responses, increased vessel wall stiffness and 
profound microvascular rarefaction.  Evidence from clinical trials indicates that the 
adverse effects of chronic COX inhibition severely outweigh therapeutic potential.  
Additionally, animal models of dyslipidemia whose lipid levels mimic those found in 
metabolic syndrome models demonstrate the very real potential of chronic COX 
therapies being ineffectual with time as a resistant phenotype emerges.  Metabolic 
syndrome individuals require a better therapeutic target for therapies to disrupt these 
COX mediated effects.  In the short term, the answers would seem to come from 
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antagonism of the TxA2 dependent pathways which have been shown to protect against 
rarefaction and blunted dilator responses in animal models of metabolic syndrome. 
 While the above mentioned therapies show promise for the short-term, where 
they fail is in a mechanistic understanding of the cause of alterations in COX metabolite 
balance.  Inhibition of the TxA2 pathway still does improve the production of 
prostacyclin.  While a more physiologic ratio of TxA2 to prostacyclin may be achievable 
simply through TxA2 pathway antagonism, this doesn’t correct the diminished sensitivity 
of the system to prostacyclin.  Chronic anti-oxidant therapies demonstrate the ability to 
confer partial protection against rarefaction along with partial restoration of normal 
vasomotor responses while also returning sensitivity of the system to prostacyclin.  This 
combined with similar effects of anti-inflammatory drugs would indicate that while the 
processes of vascular dysfunction are resulting from alterations to COX metabolite 
balances, the origin of the problem is not in AA metabolism but rather the effects of 
chronic inflammation and elevations in oxidant stress on the system.  Further studies 
are required to determine the origins of this inflammation and oxidant stress to begin to 
truly treat the root of a problem that appears to extend significantly beyond AA 
metabolism. 
 Additionally, future studies need to redouble their efforts on the understanding of 
metabolic syndrome related skeletal muscle microvascular rarefaction.  Work by Frisbee 
et al. has demonstrated that in the obese Zucker rat, when allowed to reach fully 
established metabolic syndrome symptomology, even a fully dilated vascular bed is 
incapable of matching perfusion with increased metabolic demand resulting in more 
rapid rates of fatigue and reduced maximal muscle tension development (1).  This 
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inability to match metabolic demand with perfusion is a hallmark of metabolic syndrome 
and is too readily attributed to the complex interplay of vasomotor regulators.  While 
there is no doubt that the dysregulation of the vasomotor plays a significant role in 
demand:perfusion impairment, the ability to adequately repair a complex system such 
as regulation of vascular tone will require extensive further studies.  On the contrary, 
making sure there is adequate tissue capillarity to maintain bulk flow though may be a 
much more correctable problem.  Rarefaction itself has largely been ignored owing to 
the fact that tissues work with a surplus capillarity and even when working with a deficit, 
the ability to regulate tone allows a tissue to maintain adequate perfusion much more 
readily than if vessels were passive.  This fails to take into account that with each 
capillary lost, the error term for proper vasomotor regulation must become 
proportionately smaller to maintain normal flow.  The caveat being that if tissue 
capillarity can be spared, this error term can afford to remain much larger.  Taken 
together these data suggest that further investigations into understanding the underlying 
mechanisms resulting in elevations in oxidant stress and inflammatory status are 
essential to understanding the true cause of obesity related vascular disease and that it 
is only through an understanding of the origins of these problems that a true therapeutic 
regimen against these multi-faceted vasculopathies can be developed.  
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2. You are hereby granted a personal, non-exclusive, non-sublicensable, non-transferable, 
worldwide, limited license to reproduce the Materials for the purpose specified in the licensing 
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exclusive property of John Wiley & Sons Inc or one of its related companies (WILEY) or their 
respective licensors, and your interest therein is only that of having possession of and the right to 
reproduce the Materials pursuant to Section 2 herein during the continuance of this Agreement. 
You agree that you own no right, title or interest in or to the Materials or any of the intellectual 
property rights therein. You shall have no rights hereunder other than the license as provided for 
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shall not assert any such right, license or interest with respect thereto.  
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8. IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR ANY OTHER PARTY OR 
ANY OTHER PERSON OR ENTITY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, 
EXEMPLARY OR PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN CONNECTION 
WITH THE DOWNLOADING, PROVISIONING, VIEWING OR USE OF THE MATERIALS REGARDLESS 
OF THE FORM OF ACTION, WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, 
TORT, NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT LIMITATION, 
DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, USE, BUSINESS OPPORTUNITY OR 
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illegal, invalid, or unenforceable, that provision shall be deemed amended to achieve as nearly as 
possible the same economic effect as the original provision, and the legality, validity and 
Page 2 of 5Rightslink Printable License
11/20/2011https://s100.copyright.com/App/PrintableLicenseFrame.jsp?publisherID=140&licenseID...
176
enforceability of the remaining provisions of this Agreement shall not be affected or impaired 
thereby.  
 
10. The failure of either party to enforce any term or condition of this Agreement shall not 
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license details provided by you and accepted in the course of this licensing transaction, (ii) these 
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in accordance with the terms of the Creative Commons Attribution Non Commercial License. At 
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copyediting, and publishing. Repositories and websites that host the article are responsible for 
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Wiley Open Access articles are also available without charge on Wiley's publishing platform, 
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? The authors' moral rights are not compromised. These rights include the right of 
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"integrity" (the right for the author not to have the work altered in such a way that the 
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? Where content in the article is identified as belonging to a third party, it is the obligation 
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? Copying or downloading of articles, or linking to such articles for further redistribution, 
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? Copying, downloading or posting by a site or service that incorporates advertising with 
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normal quotations with an appropriate citation) that is then available for sale or licensing, for 
a fee (for example, a compilation produced for marketing purposes, inclusion in a sales 
pack)  
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profit organisations for promotional purposes  
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educational purposes;  
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2. You are hereby granted a personal, non-exclusive, non-sublicensable, non-transferable, 
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author, title of the material/book/journal and the publisher. You shall also duplicate the copyright 
notice that appears in the Wiley publication in your use of the Material. Permission is also granted 
on the understanding that nowhere in the text is a previously published source acknowledged for 
all or part of this Material. Any third party material is expressly excluded from this permission.  
 
3. With respect to the Materials, all rights are reserved. Except as expressly granted by the terms 
of the license, no part of the Materials may be copied, modified, adapted (except for minor 
reformatting required by the new Publication), translated, reproduced, transferred or distributed, 
in any form or by any means, and no derivative works may be made based on the Materials 
without the prior permission of the respective copyright owner. You may not alter, remove or 
suppress in any manner any copyright, trademark or other notices displayed by the Materials. You 
may not license, rent, sell, loan, lease, pledge, offer as security, transfer or assign the Materials, 
or any of the rights granted to you hereunder to any other person.  
 
4. The Materials and all of the intellectual property rights therein shall at all times remain the 
exclusive property of John Wiley & Sons Inc or one of its related companies (WILEY) or their 
respective licensors, and your interest therein is only that of having possession of and the right to 
reproduce the Materials pursuant to Section 2 herein during the continuance of this Agreement. 
You agree that you own no right, title or interest in or to the Materials or any of the intellectual 
property rights therein. You shall have no rights hereunder other than the license as provided for 
above in Section 2. No right, license or interest to any trademark, trade name, service mark or 
other branding ("Marks") of WILEY or its licensors is granted hereunder, and you agree that you 
shall not assert any such right, license or interest with respect thereto.  
 
5. NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR REPRESENTATION OF ANY 
KIND TO YOU OR ANY THIRD PARTY, EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE 
MATERIALS OR THE ACCURACY OF ANY INFORMATION CONTAINED IN THE MATERIALS, 
INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY, 
ACCURACY, SATISFACTORY QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY, 
INTEGRATION OR NON-INFRINGEMENT AND ALL SUCH WARRANTIES ARE HEREBY EXCLUDED BY 
WILEY AND ITS LICENSORS AND WAIVED BY YOU.  
 
6. WILEY shall have the right to terminate this Agreement immediately upon breach of this 
Agreement by you.  
 
7. You shall indemnify, defend and hold harmless WILEY, its Licensors and their respective 
directors, officers, agents and employees, from and against any actual or threatened claims, 
demands, causes of action or proceedings arising from any breach of this Agreement by you.  
 
8. IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR ANY OTHER PARTY OR 
ANY OTHER PERSON OR ENTITY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, 
EXEMPLARY OR PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN CONNECTION 
WITH THE DOWNLOADING, PROVISIONING, VIEWING OR USE OF THE MATERIALS REGARDLESS 
OF THE FORM OF ACTION, WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, 
TORT, NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT LIMITATION, 
DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, USE, BUSINESS OPPORTUNITY OR 
CLAIMS OF THIRD PARTIES), AND WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE 
POSSIBILITY OF SUCH DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING ANY 
FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED HEREIN.  
 
9. Should any provision of this Agreement be held by a court of competent jurisdiction to be 
illegal, invalid, or unenforceable, that provision shall be deemed amended to achieve as nearly as 
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terms and conditions and (iii) CCC’s Billing and Payment terms and conditions.  
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of New York, USA, without regards to such state’s conflict of law rules. Any legal action, suit or 
proceeding arising out of or relating to these Terms and Conditions or the breach thereof shall be 
instituted in a court of competent jurisdiction in New York County in the State of New York in the 
United States of America and each party hereby consents and submits to the personal jurisdiction 
of such court, waives any objection to venue in such court and consents to service of process by 
registered or certified mail, return receipt requested, at the last known address of such party.  
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freely available to read, download and share. Articles are published under the terms of the 
Creative Commons Attribution Non Commercial License. which permits use, distribution and 
reproduction in any medium, provided the original work is properly cited and is not used for 
commercial purposes. The license is subject to the Wiley Open Access terms and conditions:  
Wiley Open Access articles are protected by copyright and are posted to repositories and websites 
in accordance with the terms of the Creative Commons Attribution Non Commercial License. At 
the time of deposit, Wiley Open Access articles include all changes made during peer review, 
copyediting, and publishing. Repositories and websites that host the article are responsible for 
incorporating any publisher-supplied amendments or retractions issued subsequently.  
Wiley Open Access articles are also available without charge on Wiley's publishing platform, 
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Use of Wiley Open Access articles for commercial, promotional, or marketing purposes 
requires further explicit permission from Wiley and will be subject to a fee. Commercial 
purposes include:  
 
? Copying or downloading of articles, or linking to such articles for further redistribution, 
sale or licensing;  
? Copying, downloading or posting by a site or service that incorporates advertising with 
such content;  
? The inclusion or incorporation of article content in other works or services (other than 
normal quotations with an appropriate citation) that is then available for sale or licensing, for 
a fee (for example, a compilation produced for marketing purposes, inclusion in a sales 
pack)  
? Use of article content (other than normal quotations with appropriate citation) by for-
profit organisations for promotional purposes  
? Linking to article content in e-mails redistributed for promotional, marketing or 
educational purposes;  
? Use for the purposes of monetary reward by means of sale, resale, licence, loan, transfer 
or other form of commercial exploitation such as marketing products  
? Print reprints of Wiley Open Access articles can be purchased from: 
corporatesales@wiley.com  
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Microvasculopathy in the Metabolic Syndrome”  Humana Press/Springer Science 
Inc.; for “Oxidative Stress in Applied Basic Science and Clinical Research” [In 
Preparation]. 
3. P.A. Stapleton, M.E. James, A.G. Goodwill, J.C. Frisbee.  Obesity and Vascular 
Dysfunction.   Pathophysiology. 2008 Aug;15(2):79-89. [Epub 2008 Jun 20]. 
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 PEER REVIEWED PUBLICATIONS 
 
1. J.T. Butcher, A.G. Goodwill, J.C. Frisbee. The Ex-Vivo Isolated Microvessel 
Preparation as a Method of Investigation into Skeletal Muscle Perfusion. The 
Journal of Visualized Experiments. [In Press] 
2. J.C. Frisbee, F. Wu, A.G. Goodwill, J.T. Butcher, and D.A. Beard. Spatial  
Heterogeneity in Skeletal Muscle Microvascular Perfusion Distribution is 
Increased in the Metabolic Syndrome. Am J Physiol Regul Integr Comp Physiol 
2011 Oct;301(4):R975-86. Epub 2011 Jul 20. PMID: 21775645 
3. J.C. Frisbee, A.G. Goodwill, J.T. Butcher, and I.M. Olfert. Divergence Between 
Arterial Perfusion and Fatigue Resistance in Skeletal Muscle in the Metabolic 
Syndrome. Exp Physiol. 2011 Mar;96(3):369-83. Epub 2010 Dec 1. 
PMID:21123363 
4. S.J. Frisbee, C.B. Chambers, J.C. Frisbee, A.G. Goodwill, and R.J. Crout. Self-
Reported Dental Hygiene, Obesity, and Systemic Inflammation in a Pediatric 
Rural Community Cohort. BMC Oral Health 2010 Sep 18;10(1):21. PMID: 
20849640 
5. J. C. Frisbee, A.G. Goodwill, P.A Stapleton, S.J. Frisbee, and A.C. d'Audiffret. 
Aspirin Resistance with Genetic Dyslipidemia: Contribution of Vascular 
Thromboxane Generation. Physiologic Genomics.  2010 Jun 8. [Epub ahead of 
print] 
PMID: 20530721  
6. S.J. Frisbee, C.B. Chambers, J.C. Frisbee, A.G. Goodwill and R.J. Crout. 
Association Between Dental Hygiene, Cardiovascular Disease Risk, and 
Systemic Inflammation in Rural Adults. J Dent Hyg. 2010;84(4):177-84. [Epub 
2010 Nov 1]. PMID: 21047463  
7. A.C. d’Audiffret, S.J. Frisbee, P.A. Stapleton,  A.G. Goodwill, M.E. James, E. 
Isingrini and J.C. Frisbee. Depressive Behavior and Vascular Dysfunction: A Link 
Between Clinical Depression AND Vascular Disease?. The Journal of Applied 
Physiology. 2010 Feb 18. [Epub ahead of print]. PMID: 20167667 
8. T.R. Nurkiewicz, D.W. Porter, A.F. Hubbs, S. Stone, A.M. Moseley, J.L. 
Cumpston, A.G. Goodwill, S.J. Frisbee, P.L. Perrotta, R.W. Brock, J.C. Frisbee, 
M.A. Boegehold, D.G. Frazer, B.T. Chen and V. Castranova.  Pulmonary 
Particulate Matter and Systemic Microvascular Dysfunction. Health Effects 
Institute [In Review], 2009. 
9. A.G. Goodwill, S.J. Frisbee, P.A. Stapleton, M.E. James and J.C. Frisbee.  
Impact of Chronic Anti-Cholesterol Therapy on Development of Microvascular 
Rarefaction in the Metabolic Syndrome.  Microcirculation. 2009 Nov;16(8):667-
84. PMID: 19905967 
10. J.B. Samora, A.G. Goodwill, J.C. Frisbee, M.A. Boegehold. Growth-Dependant 
Changes in the Contribution of Carbon Monoxide to Artertiolar Function. Journal 
of Vascular Research. 2010;47(1):23-34. [Epub 2009 Aug 6]. PMID: 19672105 
11. A.G. Goodwill, P.A. Stapleton, M.E. James, J.C. Frisbee. Increased Arachidonic 
Acid-Induced Thromboxane Generation Impairs Skeletal Muscle Arteriolar 
Dilation with Genetic Dyslipidemia. Microcirculation. 2008 Oct;15(7):621-31. 
PMID: 18720229 
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 12. A.G. Goodwill, M.E. James, J.C. Frisbee. Increased vascular thromboxane 
generation impairs dilation of skeletal muscle arterioles of obese Zucker rats with 
reduced oxygen tension. Am J Physiol Heart Circ Physiol. 2008 
Oct;295(4):H1522-8. Epub 2008 Aug 8. PMID: 18689495 
13. P.A. Stapleton, A.G. Goodwill, M.E. James, J.C. Frisbee. Altered Mechanisms 
of Endothelium-Dependent Dilation in Skeletal Muscle Arterioles with Genetic 
Hypercholesterolemia. Am J Physiol Regul Integr Comp Physiol. 2007 
Sep;293(3):R1110-9. PMID: 17626122 
14. Amy M. Jones, Adam Goodwill and T. Elliott. Limited Role for the DsrA and 
RprA Regulatory RNAs in rpoS Regulation in Salmonella enterica. J Bacteriol. 
2006 Jul;188(14):5077-88. PMID: 16816180 
 
CONFERENCE PRESENTATIONS 
 
1. Invited Lecture: Tumor necrosis factor alpha contributes to vascular dysfunction 
and skeletal muscle microvascular rarefaction in the obese Zucker rat. A.G. 
Goodwill, J.T. Butcher, J.C. Frisbee. Experimental Biology 2011/Microcirculatory 
Society President’s Symposium II, Washington D.C., District of Columbia, United 
States, 2011-04; Abstract 636.16 
2. Poster: Temporal progression of microvascular rarefaction in the metabolic 
syndrome.  A.G. Goodwill, J.C. Frisbee. Experimental Biology 2011, 
Washington D.C., District of Columbia, United States, 2011-04; Abstract 636.17 
3. Poster: Differential impact of myogenic activation on dilator responses in cerebral 
and skeletal muscle resistance arterioles of obese Zucker rats.  J.T. Butcher, 
A.G. Goodwill, J.C. Frisbee. Experimental Biology 2011, Washington D.C., 
District of Columbia, United States, 2011-04; Abstract 816.9 
4. Poster: Divergence between arterial perfusion and fatigue resistance in skeletal 
muscle in the metabolic syndrome.  J. C. Frisbee, A.G. Goodwill, J.T. Butcher, 
I.M. Olfert. Experimental Biology 2011, Washington D.C., District of Columbia, 
United States, 2011-04; Abstract 1023.7 
5. Poster: Effect of remote ischemic preconditioning on hepatic parenchymal and 
microvascular damage in obesity.  H.A. O'Leary, A. Kothur, S.B. Fournier, A.G. 
Goodwill, J.C. Frisbee, R.W. Brock. Experimental Biology 2011, Washington 
D.C., District of Columbia, United States, 2011-04; Abstract 1117.9 
6. Poster: Alterations in hepatic tumor cell colonization during obesity.  H.A. 
O'Leary, A. Kothur, A.G. Goodwill, J.C. Frisbee, R.W. Brock. Experimental 
Biology 2011, Washington D.C., District of Columbia, United States, 2011-04; 
Abstract 639.2 
7. Poster: Tumor necrosis factor alpha contributes to vascular dysfunction and 
skeletal muscle microvascular rarefaction in the obese Zucker rat. A.G. 
Goodwill, J.T. Butcher, J.C. Frisbee. Experimental Biology 2011, Washington 
D.C., District of Columbia, United States, 2011-04; Abstract 636.16 
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 8. Poster: Obesity-induced increased vascular thromboxane A2 Generation: An 
initiating stimulus for microvascular rarefaction? A.G. Goodwill, P.A. Stapleton, 
S.J. Frisbee, and J.C. Frisbee. World Congress for Microcirculation 2010, Paris 
France. 2010-09 
9. Poster: Aspirin resistance with genetic dyslipidemia: Contribution of vascular 
thromboxane generation. J.C. Frisbee, A.G. Goodwill, P.A. Stapleton, S.J. 
Frisbee, and A.C. d’Audiffret. World Congress for Microcirculation 2010, Paris, 
France. 2010-09 
10. Poster: Increased vascular generation of thromboxane A2: An initiating condition 
for microvascular rarefaction in obese Zucker rats? A.G. Goodwill, P.A. 
Stapleton, S.J. Frisbee, M.E. James and J.C. Frisbee. Experimental Biology 
2010, Anaheim, California, United States. 2010-04; Abstract 774.19 
11. Poster: Insulin resistance-independent impairments to arterial endothelial 
function with depressive symptoms in mice.  J.A.L. Beckett, M.E. James, P.A. 
Stapleton, A.G. Goodwill, A.C. d’Audiffret and J.C. Frisbee. Experimental 
Biology 2010, Anaheim, California, United States. 2010-04; Abstract 1044.3 
12. Poster: Impaired arteriolar dilation in a mouse model of familial 
hypercholesterolemia and anti-cholesterol therapy. P.A. Stapleton, A.G. 
Goodwill, M.R. Morrisette, M.E. James and J.C. Frisbee.  Experimental Biology 
2010, Anaheim, California, United States. 2010-04; Abstract 593.5 
13. Invited Lecture: Correlations between peripheral vascular function, inflammation 
and depression in human subjects.  P.A. Stapleton, A.C. d'Audiffret, S.J. Frisbee, 
A.G. Goodwill, M.E. James, and J.C. Frisbee.  Experimental Biology 2009, New 
Orleans, Louisiana, United States. 2009-04; Abstract 23:795.3. 
14. Poster: Vascular thromboxane generation restrains arteriolar hypoxic dilation in 
skeletal muscle of OZRs. A.G. Goodwill, J.M. Hollander, R.W. Brock, M.E. 
James and J.C. Frisbee. Experimental Biology 2009, New Orleans, Louisiana, 
United States. 2009-04; Abstract 23:767.9. 
15. Poster: AA-induced TxA2 generation impairs skeletal muscle arteriolar dilation 
with genetic dyslipidemia. A.G. Goodwill, P.A. Stapleton, M.E. James, A.C. 
d’Audiffret and J.C. Frisbee. Experimental Biology 2009, New Orleans, 
Louisiana, United States. 2009-04; Abstract 23:766.3. 
16. Poster: Development of a predictive model for negative microvascular outcomes 
in the metabolic syndrome. J.C. Frisbee, A.G. Goodwill, M.E. James, R.W. 
Brock, J.M. Hollander and S.J. Frisbee. Experimental Biology 2009, New 
Orleans, Louisiana, United States. 2009-04; Abstract 23:594.11. 
17. Poster: Mechanistic links between the lung and the systemic microcirculation 
after nanoparticle exposure. T.R. Nurkiewicz, M. Donlin, A.F. Hubbs, A.G. 
Goodwill, J.C. Frisbee, B.T. Chen, D.G. Frazer and V. Castranova. Society of 
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 Toxicology, Baltimore, Maryland, United States. Toxicological Sciences, March 
108 (1-S), 1353, 2009. 
18. Poster: Diesel exhaust exposure alters microvascular blood flow and wall shear 
rate. K.L. Sites, A.G. Goodwill, J.C. Frisbee and T.R. Nurkiewicz. Society of 
Toxicology, Baltimore, Maryland, United States. March 108 (1-S), 200, 2009. 
19. Invited Lecture: Metabolic Syndrome and Microvascular Rarefaction: 
Contributions from Nitric Oxide and Inflammation. J.C. Frisbee, A.G. Goodwill, 
P.A. Stapleton, M.E. James, R.W. Bryner, and S.J. Frisbee. The 25th 
Conference of the European Society for Microcirculation; Integrating Vascular 
Biology and Medicine, Budapest, Hungary. 2008-08 
20. Invited Lecture: Microvascular Adaptations to Obesity and the Metabolic 
Syndrome. J. Frisbee, A.G. Goodwill, M. James, R. Bryner, S. Frisbee. 2008 
APS Intersociety Meeting: The Integrative Biology of Exercise V, Hilton Head, 
South Carolina, United States. 2008-08 
21. Invited Lecture: The Metabolic Syndrome and Microvascular Rarefaction: 
Integrated Model for NO Bioavailability. J.C. Frisbee, A.G. Goodwill, P.A. 
Stapleton, M.E. James, R.W. Bryner, S.J. Frisbee European Society for 
Microcirculation Annual Meeting 2008, Budapest, Hungary. 2008-08 
22. Poster: Dental Habits Related to Adult Cardiovascular Disease and Systemic 
Inflammation. S.J. Frisbee, C.B. Chambers, J.C. Frisbee, A.G. Goodwill, R.J. 
Crout. The International Association for Dental Research (IADR) 37th Annual 
Meeting & Exhibition, Dallas, Texas, United States. 2008-04 
23. Poster: Dental health, cardiovascular disease risk and systemic inflammation in 
children. C.B. Chambers, S.J. Frisbee, J.C. Frisbee, A.G. Goodwill and R.J. 
Crout. The International Association for Dental Research (IADR) 37th Annual 
Meeting & Exhibition, Dallas, Texas, United States. 2008-04 
24. Poster: Arachidonic acid-induced vascular thromboxane generation in mouse 
models of atherothrombotic vascular disease. J.C. Frisbee, M.E. James, A.G. 
Goodwill and C. Khamare. 2007-05  
25. Poster: Influences of age and gender on cardiovascular disease risk factor 
associated inflammation. S.J. Frisbee, A.G. Goodwill, J.M. Delp and J.C. 
Frisbee. American Heart Association, Epidemiology Council Meeting, 2007, 
Orlando, Florida, United States. 2007-02 
26. Poster: Altered Patterns of Inflammatory Marker Expression in Plasma of Obese 
vs. Dyslipidemic Humans. S.J. Frisbee, A.G. Goodwill, M. Boegehold, W.A. 
Neal, J.C. Frisbee. North American Association for the study of obesity (NAASO) 
Annual Scientific Meeting, Boston, Massachusetts, United States. 2006-10 
27. Invited Lecture: Inflammation, NO bioavailability and the metabolic syndrome: 
interactions leading to rarefaction. J.C. Frisbee, A.G. Goodwill and S.J. Frisbee. 
Workshop on Mathematical Modeling of Microcirculation; Mathematical 
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 Biosciences Institute at Ohio State University, Columbus, Ohio, United States. 
2006-10 
28. Poster: Low Vascular NO Bioavailability-Induced Microvascular Rarefaction is not 
Associated with Angiostatin. J.C. Frisbee, M.E. James, J. Balch Samora, A.G. 
Goodwill, B. Chelladurai and D.P. Basile. Arteriosclerosis, Thrombosis and 
Vascular Biology 2006 Scientific Sessions, Washington D.C., District of 
Columbia, United States. 2006-04 
29. Lecture: Regulation of RpoS in enteric bacteria. Hirsch, M., A.M. Jones, A. 
Goodwill & T. Elliott. The Seventh Analytical Genetics Meeting, San Diego, 
California, United States. 2005-10 
30. Lecture: Production of Green Sheen Differs Depending Upon Atmospheric 
Conditions and Medium Formulations. Adam G. Goodwill, Heather A. O'Leary, 
Amanda M. Hartle, Kate H. Eggleton, and Douglas M. Smith. 2003-04 
31. Poster: Identification of the Green Sheen Gene In Uropathogenic E. coli. 
Essandoh, Eugene, Leonard Kotevski, Heather O’Leary, Adam Goodwill, Carrie 
Martz, Josh Yeykal, Rebhecca Parisi, Kate Eggleton, Douglas M. Smith. 
Commonwealth of Pennsylvania University Biologists 34th Annual Meeting, 
Shippensburg, Pennsylvania, United States. 2003-04 
32. Poster: Production of Green Sheen Differs Depending on Atmospheric 
Conditions and EMB Medium Formulations. Adam G. Goodwill, Heather A. 
O'Leary, Douglas M. Smith, Ph.D. 2002 Annual meeting of the Allegheny Branch 
of the American Society for Microbiology, Clarion, Pennsylvania, United States. 
2002-10 
33. Poster: Production Of Green Sheen Differs Depending Upon Atmospheric 
Conditions and Medium Formulations. Goodwill, A.G., H. A. O’Leary, A. M. 
Hartle, K. H. Eggleton and D. M. Smith. Commonwealth of Pennsylvania 
University Biologists 33rd Annual Meeting, Lock Haven, Pennsylvania, United 
States. 2002-04 
INSTITUTIONAL PRESENTATIONS 
 
1. Lecture: Microvascular Rarefaction in the Metabolic Syndrome: Goodwill A.G. 
The Department of Physiology & Pharmacology Julie Betschard Symposium 
2011-05 
2. Invited Lecture: Temporal Progression of Microvascular Rarefaction in the 
Metabolic Syndrome: Goodwill A.G. The West Virginia University 2011 E.J. Van 
Liere Memorial Convocation and Research Day. 2011-03 
3. Lecture: Temporal Progression of Microvascular Rarefaction in the Metabolic 
Syndrome: Goodwill A.G. The Department of Physiology and Pharmacology 
required annual seminar. 2011-02. 
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 4. Invited Lecture:  Microvascular Rarefaction in the Obese Zucker Rat: Goodwill 
A.G. The West Virginia University School of Pharmacy Research Day. 2010-10. 
5. Lecture: Increased Vascular Generation of Thromboxane A2: An Initiating 
Condition For Microvascular Rarefaction in Obese Zucker Rats? Goodwill A.G. 
The Department of Physiology & Pharmacology Julie Betschard Symposium. 
2010-05 
6. Lecture: Aspirin Resistance with Genetic Dyslipidemia: Contribution of Vascular 
Thromboxane Generation.  Goodwill A.G. The Department of Physiology and 
Pharmacology required annual seminar. 2010-04 
7. Lecture: Vascular Consequences of Obesity Induced Alterations to Arachidonic 
Acid Metabolism in Obese Zucker Rats. Goodwill A.G. The West Virginia 
University Center for Cardiovascular and Respiratory Sciences monthly work in 
progress meeting. 2009-12 
8. Lecture: Impact of Chronic Anti-Cholesterol Therapy on Development of 
Microvascular Rarefaction in the Metabolic Syndrome. Goodwill A.G. The 
Department of Physiology and Pharmacology required annual seminar. 2009-09 
9. Lecture: Increased Vascular Thromboxane Generation Restrains Arteriolar 
Dilation to Hypoxia in Obese Zucker Rats. Goodwill A.G. The Department of 
Physiology & Pharmacology Julie Betschard Symposium. 2009-05 
10. Poster: Elevated Vascular Thromboxane Generation Impairs Dilation of OZR 
Arterioles with Reduced O2 Tension. Goodwill A.G. The West Virginia University 
2009 E.J. Van Liere Memorial Convocation and Research Day.2009-04 
11. Lecture: Arachidonic Acid-Induced TxA2 Generation Impairs Arteriolar Dilation 
with Genetic Dyslipidemia. Goodwill A.G.. The Department of Physiology & 
Pharmacology Julie Betschard Symposium. 2008-05 
12. Lecture: Increased Arachidonic Acid-Induced Thromboxane Generation Impairs 
Skeletal Muscle Arteriolar Dilation with Genetic Dyslipidemia. Goodwill A.G. The 
Department of Physiology and Pharmacology required annual seminar. 2008-04 
TEACHING EXPERIENCE 
 
− Special Topics in Physiology; West Virginia University   2009 
• I facilitated a study group in which specific topics including cardiovascular, 
respiratory, and renal physiology were expanded from the perspective of 
clinical relevance. This course, designed for medical students, sought to 
integrate clinical case studies with the basic biomedical sciences required 
to understand the processes of the pathologies presented within those 
studies.  This course was facilitated by 3 separate instructors. 
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 − Cardiovascular Physiology Study Session; West Virginia University 2008-2009 
• Facilitated a 3 to 5 hour per week study group to aid select pharmacy 
professional students in increasing their understanding of cardiovascular 
physiology. I was asked to facilitate this tutoring group by the Pharmacy 
department.  This was only offered during the cardiovascular modules of 
their normal coursework each year. 
− Genetics Study Session; Clarion University    2002-2003 
• Co-taught a supplementary course designed to complement didactic 
materials for the genetics course which was required for all 
undergraduates in a biology discipline at Clarion University. This course 
reinforced concepts taught within the undergraduate genetics curriculum. 
 
INSTITUTIONAL SERVICE 
 
1. Graduate Student Representative, West Virginia University Vice President for 
Research and Development Search Committee; 2011 
2. Student Member, West Virginia University Vice President for Health Sciences 
Research and Graduate Education Search Committee; 2010 
 
SERVICE TO SCIENTIFIC SOCIETIES 
 
1. Microcirculatory Society Young Investigator Symposium Co-Chair. Experimental 
Biology, Washington D.C., District of Columbia, United States.  2011-04 
AWARDS & FELLOWSHIPS 
 
1. Runner up, Best Oral Presentation, Julie Betschart Symposium W.V.U. Dept of 
Physiology and Pharmacology  
2011 
2. Runner up, American Society for Pharmacology and Experimental Therapeutics 
Cardiovascular Section Graduate Student Best Abstract Award   
          2011 
3. Society for Experimental Biology and Medicine, Burton E. Sobel Award for 
Excellence in Cardiovascular Research 
2011 
4. American Society for Pharmacology and Experimental Therapeutics Graduate 
Student Travel Award; Experimental Biology 
2011 
5. Runner up, Best Oral Presentation The West Virginia University E.J. Van Liere 
Memorial Convocation/ 
2011 
6. Best Oral Presentation, Julie Betschart Symposium W.V.U. Dept of Physiology 
and Pharmacology          
2010 
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 7. ORAU-Fellowship for 60th Annual Lindau Meeting of Nobel Laureates in 
Chemistry, Physics, and Physiology/Medicine Lindau, Germany  
2010 
8. American Heart Association – Great Rivers Affiliate “Early Microvascular 
Rarefaction in Metabolic Syndrome” 10PRE3040016 
          2010-2012  
9. Research Training in Cardiovascular and Pulmonary Diseases (Predoctoral 
Fellowship)  5T32HL090610-02.    
          2009-2010 
10. Best Oral Presentation, Julie Betschart Symposium W.V.U. Dept of Physiology 
and Pharmacology       
          2009 
11. Zweifach Student Travel Award, Microcirculatory Society 
          2009 
12. Best Oral Presentation CPUB      
          2003  
13. Best Poster Presentation CPUB      
          2002  
14. Runner up, Best Poster Presentation ABASM    
          2002  
 
PROFESSIONAL SOCIETY MEMBERSHIPS 
 
1. Society for Experimental Biology & Medicine, 2011 (Student Member) 
2. American Physiological Society, 2011 (Student Member) 
3. American Society for Pharmacology and Experimental Therapeutics, 2011 
(Student Member) 
4. Microcirculatory Society, USA 2009-2011 (Student Member) 
5. American Society for Microbiology 2001-2003 (Student Member) 
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